[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fG1oJk68E5r4DcQnqs_NZQrp407thiM2WJrKrRCzGja0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":37,"phaseBuckets":38,"rows":45},"Novartis Vaccines",[4],165,false,0,77,337891,8,[13,16,19,22,25,28,31,34],{"name":14,"count":15},"Meningococcal Disease",34,{"name":17,"count":18},"Influenza",30,{"name":20,"count":21},"Meningococcal Meningitis",22,{"name":23,"count":24},"Seasonal Influenza",10,{"name":26,"count":27},"Human Influenza",7,{"name":29,"count":30},"Meningococcal Infections",6,{"name":32,"count":33},"Rabies",5,{"name":35,"count":36},"Pandemic Influenza",4,[],[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,90,125,151,177,195,219,244,262,287,312,388,444,499,576,640,681,721,759,796,825,854,876,903,936,969,1002,1024,1046,1070,1092,1114,1136,1166,1198,1231,1262,1297,1320,1338,1356,1378,1402,1420,1442,1460,1478,1500,1518,1548,1566,1584,1602,1620,1638,1656,1674,1698,1721,1739,1757,1775,1793,1811,1829,1854,1872,1890,1908,1926,1944,1962,1980,1998,2016,2042,2060,2078,2096,2114,2137,2155,2173,2191,2209,2234,2252,2270,2294,2312,2335,2353,2371,2394,2412,2439,2465,2489,2507,2531,2549,2573,2591,2609,2627,2645,2668,2694,2712,2730,2754,2775,2796,2819,2837,2855,2873,2891,2914,2938,2956,2979,2997,3015,3033,3057,3075,3093,3117,3135,3153,3176,3194,3212,3230,3248,3273,3291,3321,3354,3391,3417,3444,3466,3488,3510,3543,3565,3587,3621,3643,3667,3685,3703,3726,3744,3769,3787,3809,3831,3853,3877,3900,3924,3942,3963,3981,4005,4023,4049,4067,4085,4103,4125,4147,4168,4186,4204,4226,4244,4262,4280,4298,4316,4339,4365,4383,4401,4419,4437,4460,4481,4505,4523,4549,4567,4585,4603,4621,4639,4663,4681,4699,4722,4740,4762,4784,4807,4825,4850,4868,4894,4912,4930,4948,4970,4993,5014,5035,5060,5078,5108,5131,5154,5182,5200,5218,5236,5313,5339],{"intervention":47,"totalTrials":48,"cells":49},"Meningococcal C conjugate vaccine",3,{"EARLY_PHASE1":50,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":69,"NA":88},{"trials":51,"activeCount":8},[],{"trials":53,"activeCount":8},[],{"trials":55,"activeCount":8},[],{"trials":57,"activeCount":8},[58],{"nctId":59,"briefTitle":60,"status":61,"phases":62,"primaryCompletion":63,"completion":63,"start":64,"enrollment":65,"conditions":66,"interventions":68},"NCT00311415","Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children","COMPLETED",[42],"2008-04","2005-10",257,[67],"Prevention of Meningococcal Infection",[47],{"trials":70,"activeCount":8},[71,80],{"nctId":72,"briefTitle":73,"status":61,"phases":74,"primaryCompletion":75,"completion":75,"start":76,"enrollment":77,"conditions":78,"interventions":79},"NCT00310713","Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine",[43],"2006-08","2006-04",33,[67],[47],{"nctId":81,"briefTitle":82,"status":61,"phases":83,"primaryCompletion":64,"completion":64,"start":84,"enrollment":85,"conditions":86,"interventions":87},"NCT00316654","Persistence of Antibody Response to N. Meningitidis Group C in Children",[43],"2005-02",489,[67],[47],{"trials":89,"activeCount":8},[],{"intervention":91,"totalTrials":92,"cells":93},"Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine",2,{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":111,"NA":123},{"trials":95,"activeCount":8},[],{"trials":97,"activeCount":8},[],{"trials":99,"activeCount":8},[],{"trials":101,"activeCount":8},[102],{"nctId":103,"briefTitle":104,"status":61,"phases":105,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":110},"NCT01148017","Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine",[42],"2013-04","2010-07",433,[20],[91],{"trials":112,"activeCount":8},[113],{"nctId":114,"briefTitle":115,"status":61,"phases":116,"primaryCompletion":117,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":122},"NCT01823536","Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose",[43],"2013-10","2014-06","2013-05",465,[14],[91],{"trials":124,"activeCount":8},[],{"intervention":126,"totalTrials":127,"cells":128},"Haemophilus influenza type b conjugate vaccine",1,{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":137,"NA":149},{"trials":130,"activeCount":8},[],{"trials":132,"activeCount":8},[],{"trials":134,"activeCount":8},[],{"trials":136,"activeCount":8},[],{"trials":138,"activeCount":8},[139],{"nctId":140,"briefTitle":141,"status":61,"phases":142,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":148},"NCT01404962","Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children",[43],"2012-07","2011-08",764,[147],"Haemophilus Influenzae Type B Infection",[126],{"trials":150,"activeCount":8},[],{"intervention":152,"totalTrials":127,"cells":153},"Cell-derived influenza vaccine",{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":160,"PHASE4":162,"NA":175},{"trials":155,"activeCount":8},[],{"trials":157,"activeCount":8},[],{"trials":159,"activeCount":8},[],{"trials":161,"activeCount":8},[],{"trials":163,"activeCount":8},[164],{"nctId":165,"briefTitle":166,"status":61,"phases":167,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":173},"NCT00560066","Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions",[43],"2008-07","2007-11",1398,[23,172],"Vaccine",[152,174],"Egg-derived influenza vaccine",{"trials":176,"activeCount":8},[],{"intervention":174,"totalTrials":127,"cells":178},{"EARLY_PHASE1":179,"PHASE1":181,"PHASE2":183,"PHASE3":185,"PHASE4":187,"NA":193},{"trials":180,"activeCount":8},[],{"trials":182,"activeCount":8},[],{"trials":184,"activeCount":8},[],{"trials":186,"activeCount":8},[],{"trials":188,"activeCount":8},[189],{"nctId":165,"briefTitle":166,"status":61,"phases":190,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":191,"interventions":192},[43],[23,172],[152,174],{"trials":194,"activeCount":8},[],{"intervention":196,"totalTrials":127,"cells":197},"Purified Chick Embryo Cell Inactivated Rabies Vaccine",{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":204,"PHASE4":206,"NA":217},{"trials":199,"activeCount":8},[],{"trials":201,"activeCount":8},[],{"trials":203,"activeCount":8},[],{"trials":205,"activeCount":8},[],{"trials":207,"activeCount":8},[208],{"nctId":209,"briefTitle":210,"status":61,"phases":211,"primaryCompletion":212,"completion":212,"start":213,"enrollment":214,"conditions":215,"interventions":216},"NCT01365494","Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules",[43],"2011-11","2011-07",250,[32],[196],{"trials":218,"activeCount":8},[],{"intervention":220,"totalTrials":127,"cells":221},"Fluad_MF59-adjuvanted trivalent influenza subunit vaccine",{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":230,"NA":242},{"trials":223,"activeCount":8},[],{"trials":225,"activeCount":8},[],{"trials":227,"activeCount":8},[],{"trials":229,"activeCount":8},[],{"trials":231,"activeCount":8},[232],{"nctId":233,"briefTitle":234,"status":61,"phases":235,"primaryCompletion":236,"completion":236,"start":237,"enrollment":238,"conditions":239,"interventions":240},"NCT01222403","A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older",[43],"2014-10","2010-10",767,[17],[220,241],"Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine",{"trials":243,"activeCount":8},[],{"intervention":241,"totalTrials":127,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":252,"PHASE4":254,"NA":260},{"trials":247,"activeCount":8},[],{"trials":249,"activeCount":8},[],{"trials":251,"activeCount":8},[],{"trials":253,"activeCount":8},[],{"trials":255,"activeCount":8},[256],{"nctId":233,"briefTitle":234,"status":61,"phases":257,"primaryCompletion":236,"completion":236,"start":237,"enrollment":238,"conditions":258,"interventions":259},[43],[17],[220,241],{"trials":261,"activeCount":8},[],{"intervention":263,"totalTrials":127,"cells":264},"Emulsion, Cell Culture-based, influenza HA vaccine H1N1",{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":273,"NA":285},{"trials":266,"activeCount":8},[],{"trials":268,"activeCount":8},[],{"trials":270,"activeCount":8},[],{"trials":272,"activeCount":8},[],{"trials":274,"activeCount":8},[275],{"nctId":276,"briefTitle":277,"status":61,"phases":278,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":284},"NCT01069367","Open-label, Uncontrolled Postmarketing Study of Cell-derived A\u002FH1N1 Influenza HA Vaccine in Japanese Elderly Subjects",[43],"2010-04","2010-03",100,[283],"Swine-Origin Influenza A H1N1 Virus",[263],{"trials":286,"activeCount":8},[],{"intervention":288,"totalTrials":127,"cells":289},"TBE vaccine for adults",{"EARLY_PHASE1":290,"PHASE1":292,"PHASE2":294,"PHASE3":296,"PHASE4":298,"NA":310},{"trials":291,"activeCount":8},[],{"trials":293,"activeCount":8},[],{"trials":295,"activeCount":8},[],{"trials":297,"activeCount":8},[],{"trials":299,"activeCount":8},[300],{"nctId":301,"briefTitle":302,"status":61,"phases":303,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":309},"NCT00387634","Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults",[43],"2011-10","2006-09",323,[308],"Tick Born Encephalitis",[288],{"trials":311,"activeCount":8},[],{"intervention":313,"totalTrials":30,"cells":314},"rMenB+OMV NZ",{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":342,"PHASE4":384,"NA":386},{"trials":316,"activeCount":8},[],{"trials":318,"activeCount":8},[],{"trials":320,"activeCount":8},[321,332],{"nctId":322,"briefTitle":323,"status":61,"phases":324,"primaryCompletion":325,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":330},"NCT01026974","Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine",[41],"2010-09","2012-05","2010-02",120,[14],[331,313],"rMenB",{"nctId":333,"briefTitle":334,"status":61,"phases":335,"primaryCompletion":107,"completion":107,"start":336,"enrollment":337,"conditions":338,"interventions":339},"NCT00721396","Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules",[41],"2008-08",1885,[29],[313,340,341],"combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine","Pneumococcal vaccine",{"trials":343,"activeCount":8},[344,353,364,374],{"nctId":345,"briefTitle":346,"status":61,"phases":347,"primaryCompletion":279,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":352},"NCT00661713","Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules",[41,42],"2010-12","2008-06",1631,[14],[313],{"nctId":354,"briefTitle":355,"status":61,"phases":356,"primaryCompletion":144,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":361},"NCT00944034","Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12",[41,42],"2012-01","2009-07",1588,[14,20],[362,362,313,313,362,362,363,362,363,313,363,362],"rMenB+OMV NZ with routine vaccinations","two doses of rMenB+OMV NZ",{"nctId":365,"briefTitle":366,"status":61,"phases":367,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":373},"NCT01139021","One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age",[42],"2010-11","2011-09","2010-06",508,[14],[313],{"nctId":375,"briefTitle":376,"status":61,"phases":377,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":383},"NCT01911221","A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.",[42],"2014-04","2013-08",13,[382],"Prevention of the Meningococcal Disease",[313],{"trials":385,"activeCount":8},[],{"trials":387,"activeCount":8},[],{"intervention":389,"totalTrials":33,"cells":390},"Monovalent A\u002FH1N1 influenza vaccine",{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":408,"PHASE4":440,"NA":442},{"trials":392,"activeCount":8},[],{"trials":394,"activeCount":8},[],{"trials":396,"activeCount":8},[397],{"nctId":398,"briefTitle":399,"status":61,"phases":400,"primaryCompletion":401,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":407},"NCT00992212","Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009\u002F10",[41],"2009-10","2009-11","2009-08",418,[406],"Pandemic Influenza Disease",[389],{"trials":409,"activeCount":8},[410,417,425,433],{"nctId":411,"briefTitle":412,"status":61,"phases":413,"primaryCompletion":280,"completion":144,"start":403,"enrollment":414,"conditions":415,"interventions":416},"NCT00971100","Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A\u002FH1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age",[42],752,[35],[389],{"nctId":418,"briefTitle":419,"status":61,"phases":420,"primaryCompletion":401,"completion":421,"start":403,"enrollment":422,"conditions":423,"interventions":424},"NCT00970177","Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A\u002FH1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age",[42],"2011-03",812,[35],[389],{"nctId":426,"briefTitle":427,"status":61,"phases":428,"primaryCompletion":327,"completion":213,"start":429,"enrollment":430,"conditions":431,"interventions":432},"NCT00971542","Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A\u002FH1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age",[42],"2009-09",778,[35],[389],{"nctId":434,"briefTitle":419,"status":61,"phases":435,"primaryCompletion":401,"completion":436,"start":403,"enrollment":437,"conditions":438,"interventions":439},"NCT00971906",[42],"2011-04",660,[35],[389],{"trials":441,"activeCount":8},[],{"trials":443,"activeCount":8},[],{"intervention":445,"totalTrials":33,"cells":446},"Seasonal Influenza Vaccine",{"EARLY_PHASE1":447,"PHASE1":449,"PHASE2":451,"PHASE3":477,"PHASE4":495,"NA":497},{"trials":448,"activeCount":8},[],{"trials":450,"activeCount":8},[],{"trials":452,"activeCount":8},[453,462,469],{"nctId":454,"briefTitle":455,"status":61,"phases":456,"primaryCompletion":457,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":461},"NCT01344057","Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012",[41],"2011-06","2011-05",63,[23],[445],{"nctId":463,"briefTitle":464,"status":61,"phases":465,"primaryCompletion":458,"completion":457,"start":458,"enrollment":466,"conditions":467,"interventions":468},"NCT01357265","Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects",[41],125,[17],[445],{"nctId":470,"briefTitle":471,"status":61,"phases":472,"primaryCompletion":168,"completion":168,"start":349,"enrollment":473,"conditions":474,"interventions":476},"NCT00734734","Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009",[41],64,[475],"Interpandemic Influenza",[445],{"trials":478,"activeCount":8},[479,487],{"nctId":480,"briefTitle":481,"status":61,"phases":482,"primaryCompletion":304,"completion":304,"start":369,"enrollment":483,"conditions":484,"interventions":485},"NCT01422512","Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects",[42],126,[17],[486],"seasonal influenza vaccine",{"nctId":488,"briefTitle":489,"status":61,"phases":490,"primaryCompletion":168,"completion":168,"start":349,"enrollment":491,"conditions":492,"interventions":494},"NCT00735410","Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008\u002F2009",[42],134,[493],"Seasonal Influenza, Vaccine",[445],{"trials":496,"activeCount":8},[],{"trials":498,"activeCount":8},[],{"intervention":500,"totalTrials":33,"cells":501},"MMR",{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":562,"PHASE4":572,"NA":574},{"trials":503,"activeCount":8},[],{"trials":505,"activeCount":8},[],{"trials":507,"activeCount":8},[508,522,540,552],{"nctId":509,"briefTitle":510,"status":61,"phases":511,"primaryCompletion":512,"completion":336,"start":305,"enrollment":513,"conditions":514,"interventions":516},"NCT00381615","Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety\u002FEfficacy Study",[41],"2007-07",147,[515],"Healthy",[331,517,518,519,520,521,500],"rMenB+OMV","DTaP-Hib-IPV","PC7","MenC-CRM","MenC-Hib",{"nctId":523,"briefTitle":524,"status":61,"phases":525,"primaryCompletion":526,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":532},"NCT00262002","Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants",[41],"2005-07","2006-10","2004-09",601,[531],"Prevention of Meningococcal Disease",[533,534,535,536,537,500,538,539],"MenACWY Ad-","MenACWY Ad+","MenACWY PS","HBV","Prevnar","DTaPHibIPV","Menjugate",{"nctId":541,"briefTitle":542,"status":61,"phases":543,"primaryCompletion":544,"completion":545,"start":512,"enrollment":546,"conditions":547,"interventions":548},"NCT00488683","B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants",[41],"2009-05","2009-06",216,[14],[549,518,550,500,551],"MenACWY-CRM","PCV","Hib",{"nctId":553,"briefTitle":554,"status":61,"phases":555,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":559,"interventions":560},"NCT00310856","Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)",[41],"2006-11","2005-06",175,[20],[549,520,518,519,500,561],"Varicella",{"trials":563,"activeCount":8},[564],{"nctId":565,"briefTitle":566,"status":61,"phases":567,"primaryCompletion":212,"completion":212,"start":402,"enrollment":568,"conditions":569,"interventions":570},"NCT01000311","A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months",[42],529,[14],[549,571,536,550,500],"DTaP-IPV\u002FHib",{"trials":573,"activeCount":8},[],{"trials":575,"activeCount":8},[],{"intervention":577,"totalTrials":36,"cells":578},"Meningococcal ACWY Conjugate Vaccine",{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":583,"PHASE3":585,"PHASE4":636,"NA":638},{"trials":580,"activeCount":8},[],{"trials":582,"activeCount":8},[],{"trials":584,"activeCount":8},[],{"trials":586,"activeCount":8},[587,600,616,625],{"nctId":588,"briefTitle":589,"status":61,"phases":590,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":595,"interventions":596},"NCT00474487","A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults",[42],"2007-08","2008-02","2007-05",2831,[20,29],[597,598,577,599],"Meningococcal ACWY Polysaccharide Vaccine","MenACWY CRM","Novartis MenACWY Vaccine",{"nctId":601,"briefTitle":602,"status":61,"phases":603,"primaryCompletion":604,"completion":402,"start":605,"enrollment":606,"conditions":607,"interventions":609},"NCT00474526","A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants",[42],"2008-09","2007-03",4545,[608],"Meningitis, Meningococcal",[577,610,551,611,612,613,614,615],"DTaP-IPV-HBV","Rotavirus","Pneumococcal 7-valent Conjugate Vaccine","HAV","MMR-V","DTaP",{"nctId":617,"briefTitle":618,"status":61,"phases":619,"primaryCompletion":591,"completion":620,"start":605,"enrollment":621,"conditions":622,"interventions":623},"NCT00450437","A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults",[42],"2008-01",3539,[29,20],[598,624],"Meningococcal ACWY Conjugate vaccine",{"nctId":626,"briefTitle":627,"status":61,"phases":628,"primaryCompletion":593,"completion":629,"start":76,"enrollment":630,"conditions":631,"interventions":632},"NCT00329901","Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years",[42],"2007-12",1072,[14,20],[633,634,635],"Meningococcal ACWY conjugate vaccine","Combined tetanus, reduced diphtheria and acellular pertussis vaccine","saline placebo",{"trials":637,"activeCount":8},[],{"trials":639,"activeCount":8},[],{"intervention":641,"totalTrials":48,"cells":642},"Adjuvanted influenza vaccine",{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":656,"PHASE3":667,"PHASE4":677,"NA":679},{"trials":644,"activeCount":8},[],{"trials":646,"activeCount":8},[647],{"nctId":648,"briefTitle":649,"status":61,"phases":650,"primaryCompletion":336,"completion":336,"start":349,"enrollment":651,"conditions":652,"interventions":653},"NCT00735020","Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines",[40],72,[17],[654,655],"Adjuvanted Influenza Vaccine","Influenza Vaccine",{"trials":657,"activeCount":8},[658],{"nctId":659,"briefTitle":660,"status":61,"phases":661,"primaryCompletion":512,"completion":512,"start":662,"enrollment":663,"conditions":664,"interventions":666},"NCT00522067","Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases.",[41],"2007-06",52,[665],"Influenza Disease",[641],{"trials":668,"activeCount":8},[669],{"nctId":670,"briefTitle":671,"status":61,"phases":672,"primaryCompletion":673,"completion":593,"start":556,"enrollment":674,"conditions":675,"interventions":676},"NCT00519064","Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases",[42],"2006-12",361,[665],[641],{"trials":678,"activeCount":8},[],{"trials":680,"activeCount":8},[],{"intervention":682,"totalTrials":48,"cells":683},"TIV",{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":697,"PHASE4":717,"NA":719},{"trials":685,"activeCount":8},[],{"trials":687,"activeCount":8},[],{"trials":689,"activeCount":8},[690],{"nctId":691,"briefTitle":692,"status":61,"phases":693,"primaryCompletion":379,"completion":379,"start":694,"enrollment":483,"conditions":695,"interventions":696},"NCT01879553","Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013\u002F2014, in Healthy Adults Aged 18 Years and Above",[41],"2013-07",[26],[682],{"trials":698,"activeCount":8},[699,708],{"nctId":700,"briefTitle":701,"status":61,"phases":702,"primaryCompletion":421,"completion":369,"start":325,"enrollment":703,"conditions":704,"interventions":705},"NCT01209780","Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age",[42],3116,[23],[682,706,707],"TIVf","Comparator TIV",{"nctId":709,"briefTitle":710,"status":61,"phases":711,"primaryCompletion":712,"completion":712,"start":117,"enrollment":713,"conditions":714,"interventions":715},"NCT01998477","A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to \u003C18 Years of Age at Risk for Influenza-Related Complications",[42],"2014-07",430,[17],[716,682],"TIVc",{"trials":718,"activeCount":8},[],{"trials":720,"activeCount":8},[],{"intervention":706,"totalTrials":48,"cells":722},{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":727,"PHASE3":729,"PHASE4":755,"NA":757},{"trials":724,"activeCount":8},[],{"trials":726,"activeCount":8},[],{"trials":728,"activeCount":8},[],{"trials":730,"activeCount":8},[731,735,742],{"nctId":700,"briefTitle":701,"status":61,"phases":732,"primaryCompletion":421,"completion":369,"start":325,"enrollment":703,"conditions":733,"interventions":734},[42],[23],[682,706,707],{"nctId":736,"briefTitle":737,"status":61,"phases":738,"primaryCompletion":739,"completion":739,"start":379,"enrollment":466,"conditions":740,"interventions":741},"NCT01885117","Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above",[42],"2013-09",[26],[706],{"nctId":743,"briefTitle":744,"status":61,"phases":745,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":749,"interventions":751},"NCT02256488","Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects",[42],"2014-12","2014-09",1561,[750],"Prophylaxis: Influenza",[752,753,754,706],"TIVc_LOT A","TIVc_LOT B","TIVc_LOT C",{"trials":756,"activeCount":8},[],{"trials":758,"activeCount":8},[],{"intervention":760,"totalTrials":92,"cells":761},"Egg-derived trivalent subunit influenza vaccine",{"EARLY_PHASE1":762,"PHASE1":764,"PHASE2":766,"PHASE3":768,"PHASE4":792,"NA":794},{"trials":763,"activeCount":8},[],{"trials":765,"activeCount":8},[],{"trials":767,"activeCount":8},[],{"trials":769,"activeCount":8},[770,780],{"nctId":771,"briefTitle":772,"status":61,"phases":773,"primaryCompletion":774,"completion":775,"start":528,"enrollment":776,"conditions":777,"interventions":778},"NCT00492063","Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly",[42],"2004-12","2005-05",2654,[17],[779,760],"Cell culture-derived trivalent subunit influenza vaccine",{"nctId":781,"briefTitle":782,"status":61,"phases":783,"primaryCompletion":64,"completion":76,"start":784,"enrollment":785,"conditions":786,"interventions":787},"NCT00310804","Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to \u003C=60)",[42],"2005-09",1200,[17],[788,789,790,791],"Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1","Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2","Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3","Egg-Derived Trivalent Subunit Influenza Vaccine",{"trials":793,"activeCount":8},[],{"trials":795,"activeCount":8},[],{"intervention":797,"totalTrials":92,"cells":798},"Trivalent influenza virus vaccine",{"EARLY_PHASE1":799,"PHASE1":801,"PHASE2":803,"PHASE3":811,"PHASE4":821,"NA":823},{"trials":800,"activeCount":8},[],{"trials":802,"activeCount":8},[],{"trials":804,"activeCount":8},[805],{"nctId":806,"briefTitle":807,"status":61,"phases":808,"primaryCompletion":143,"completion":143,"start":143,"enrollment":483,"conditions":809,"interventions":810},"NCT01636102","Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above",[41],[26],[797],{"trials":812,"activeCount":8},[813],{"nctId":814,"briefTitle":815,"status":61,"phases":816,"primaryCompletion":817,"completion":817,"start":143,"enrollment":483,"conditions":818,"interventions":820},"NCT01640327","Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above",[42],"2012-08",[819,17],"Human",[797],{"trials":822,"activeCount":8},[],{"trials":824,"activeCount":8},[],{"intervention":826,"totalTrials":92,"cells":827},"Haemophilus influenzae type b (Hib) vaccine",{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":832,"PHASE3":834,"PHASE4":850,"NA":852},{"trials":829,"activeCount":8},[],{"trials":831,"activeCount":8},[],{"trials":833,"activeCount":8},[],{"trials":835,"activeCount":8},[836,844],{"nctId":837,"briefTitle":838,"status":61,"phases":839,"primaryCompletion":107,"completion":348,"start":279,"enrollment":840,"conditions":841,"interventions":843},"NCT01044316","Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China",[42],670,[842],"Haemophilus Influenzae Type b (Hib) Infection",[826],{"nctId":845,"briefTitle":846,"status":61,"phases":847,"primaryCompletion":348,"completion":421,"start":237,"enrollment":437,"conditions":848,"interventions":849},"NCT01226953","Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants",[42],[842],[826],{"trials":851,"activeCount":8},[],{"trials":853,"activeCount":8},[],{"intervention":598,"totalTrials":92,"cells":855},{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":862,"PHASE4":872,"NA":874},{"trials":857,"activeCount":8},[],{"trials":859,"activeCount":8},[],{"trials":861,"activeCount":8},[],{"trials":863,"activeCount":8},[864,868],{"nctId":588,"briefTitle":589,"status":61,"phases":865,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":866,"interventions":867},[42],[20,29],[597,598,577,599],{"nctId":617,"briefTitle":618,"status":61,"phases":869,"primaryCompletion":591,"completion":620,"start":605,"enrollment":621,"conditions":870,"interventions":871},[42],[29,20],[598,624],{"trials":873,"activeCount":8},[],{"trials":875,"activeCount":8},[],{"intervention":877,"totalTrials":92,"cells":878},"Saline Placebo",{"EARLY_PHASE1":879,"PHASE1":881,"PHASE2":883,"PHASE3":885,"PHASE4":899,"NA":901},{"trials":880,"activeCount":8},[],{"trials":882,"activeCount":8},[],{"trials":884,"activeCount":8},[],{"trials":886,"activeCount":8},[887,895],{"nctId":888,"briefTitle":889,"status":61,"phases":890,"primaryCompletion":421,"completion":421,"start":348,"enrollment":891,"conditions":892,"interventions":893},"NCT01274897","A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea",[42],450,[14,20],[894,877],"Novartis MenACWY-CRM",{"nctId":626,"briefTitle":627,"status":61,"phases":896,"primaryCompletion":593,"completion":629,"start":76,"enrollment":630,"conditions":897,"interventions":898},[42],[14,20],[633,634,635],{"trials":900,"activeCount":8},[],{"trials":902,"activeCount":8},[],{"intervention":539,"totalTrials":92,"cells":904},{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":915,"PHASE4":932,"NA":934},{"trials":906,"activeCount":8},[],{"trials":908,"activeCount":8},[],{"trials":910,"activeCount":8},[911],{"nctId":523,"briefTitle":524,"status":61,"phases":912,"primaryCompletion":526,"completion":527,"start":528,"enrollment":529,"conditions":913,"interventions":914},[41],[531],[533,534,535,536,537,500,538,539],{"trials":916,"activeCount":8},[917],{"nctId":918,"briefTitle":919,"status":61,"phases":920,"primaryCompletion":921,"completion":921,"start":922,"enrollment":923,"conditions":924,"interventions":926},"NCT00657709","Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants",[42],"2010-01","2008-03",3630,[925],"Serogroup B Meningococcal Meningitis",[927,928,929,930,539,931],"Serogroup B meningococcal Vaccine lot 1","Serogroup B meningococcal Vaccine lot 2","Serogroup B meningococcal Vaccine lot 3","Infanrix Hexa","Prevenar",{"trials":933,"activeCount":8},[],{"trials":935,"activeCount":8},[],{"intervention":937,"totalTrials":92,"cells":938},"Monovalent inactivated influenza vaccine",{"EARLY_PHASE1":939,"PHASE1":941,"PHASE2":943,"PHASE3":954,"PHASE4":965,"NA":967},{"trials":940,"activeCount":8},[],{"trials":942,"activeCount":8},[],{"trials":944,"activeCount":8},[945],{"nctId":946,"briefTitle":947,"status":61,"phases":948,"primaryCompletion":358,"completion":402,"start":949,"enrollment":950,"conditions":951,"interventions":953},"NCT00841646","Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects",[41],"2008-12",343,[952],"Prepandemic Influenza Vaccine",[937],{"trials":955,"activeCount":8},[956],{"nctId":957,"briefTitle":958,"status":61,"phases":959,"primaryCompletion":545,"completion":545,"start":960,"enrollment":961,"conditions":962,"interventions":964},"NCT00848029","Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules",[42],"2008-11",240,[963],"Pre-pandemic Influenza Vaccine",[937],{"trials":966,"activeCount":8},[],{"trials":968,"activeCount":8},[],{"intervention":970,"totalTrials":92,"cells":971},"QIVc",{"EARLY_PHASE1":972,"PHASE1":974,"PHASE2":976,"PHASE3":978,"PHASE4":998,"NA":1000},{"trials":973,"activeCount":8},[],{"trials":975,"activeCount":8},[],{"trials":977,"activeCount":8},[],{"trials":979,"activeCount":8},[980,991],{"nctId":981,"briefTitle":982,"status":61,"phases":983,"primaryCompletion":984,"completion":984,"start":985,"enrollment":986,"conditions":987,"interventions":988},"NCT01992107","Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old",[42],"2014-08","2013-11",2333,[17],[970,989,990],"TIV1c","TIV2c",{"nctId":992,"briefTitle":993,"status":61,"phases":994,"primaryCompletion":712,"completion":712,"start":985,"enrollment":995,"conditions":996,"interventions":997},"NCT01992094","Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older",[42],2680,[17],[970,989,990],{"trials":999,"activeCount":8},[],{"trials":1001,"activeCount":8},[],{"intervention":989,"totalTrials":92,"cells":1003},{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1010,"PHASE4":1020,"NA":1022},{"trials":1005,"activeCount":8},[],{"trials":1007,"activeCount":8},[],{"trials":1009,"activeCount":8},[],{"trials":1011,"activeCount":8},[1012,1016],{"nctId":981,"briefTitle":982,"status":61,"phases":1013,"primaryCompletion":984,"completion":984,"start":985,"enrollment":986,"conditions":1014,"interventions":1015},[42],[17],[970,989,990],{"nctId":992,"briefTitle":993,"status":61,"phases":1017,"primaryCompletion":712,"completion":712,"start":985,"enrollment":995,"conditions":1018,"interventions":1019},[42],[17],[970,989,990],{"trials":1021,"activeCount":8},[],{"trials":1023,"activeCount":8},[],{"intervention":990,"totalTrials":92,"cells":1025},{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1030,"PHASE3":1032,"PHASE4":1042,"NA":1044},{"trials":1027,"activeCount":8},[],{"trials":1029,"activeCount":8},[],{"trials":1031,"activeCount":8},[],{"trials":1033,"activeCount":8},[1034,1038],{"nctId":981,"briefTitle":982,"status":61,"phases":1035,"primaryCompletion":984,"completion":984,"start":985,"enrollment":986,"conditions":1036,"interventions":1037},[42],[17],[970,989,990],{"nctId":992,"briefTitle":993,"status":61,"phases":1039,"primaryCompletion":712,"completion":712,"start":985,"enrollment":995,"conditions":1040,"interventions":1041},[42],[17],[970,989,990],{"trials":1043,"activeCount":8},[],{"trials":1045,"activeCount":8},[],{"intervention":716,"totalTrials":92,"cells":1047},{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1052,"PHASE3":1054,"PHASE4":1066,"NA":1068},{"trials":1049,"activeCount":8},[],{"trials":1051,"activeCount":8},[],{"trials":1053,"activeCount":8},[],{"trials":1055,"activeCount":8},[1056,1062],{"nctId":1057,"briefTitle":1058,"status":61,"phases":1059,"primaryCompletion":739,"completion":739,"start":379,"enrollment":483,"conditions":1060,"interventions":1061},"NCT01880697","Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above",[42],[26],[716],{"nctId":709,"briefTitle":710,"status":61,"phases":1063,"primaryCompletion":712,"completion":712,"start":117,"enrollment":713,"conditions":1064,"interventions":1065},[42],[17],[716,682],{"trials":1067,"activeCount":8},[],{"trials":1069,"activeCount":8},[],{"intervention":551,"totalTrials":92,"cells":1071},{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1082,"PHASE4":1088,"NA":1090},{"trials":1073,"activeCount":8},[],{"trials":1075,"activeCount":8},[],{"trials":1077,"activeCount":8},[1078],{"nctId":541,"briefTitle":542,"status":61,"phases":1079,"primaryCompletion":544,"completion":545,"start":512,"enrollment":546,"conditions":1080,"interventions":1081},[41],[14],[549,518,550,500,551],{"trials":1083,"activeCount":8},[1084],{"nctId":601,"briefTitle":602,"status":61,"phases":1085,"primaryCompletion":604,"completion":402,"start":605,"enrollment":606,"conditions":1086,"interventions":1087},[42],[608],[577,610,551,611,612,613,614,615],{"trials":1089,"activeCount":8},[],{"trials":1091,"activeCount":8},[],{"intervention":536,"totalTrials":92,"cells":1093},{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1098,"PHASE3":1104,"PHASE4":1110,"NA":1112},{"trials":1095,"activeCount":8},[],{"trials":1097,"activeCount":8},[],{"trials":1099,"activeCount":8},[1100],{"nctId":523,"briefTitle":524,"status":61,"phases":1101,"primaryCompletion":526,"completion":527,"start":528,"enrollment":529,"conditions":1102,"interventions":1103},[41],[531],[533,534,535,536,537,500,538,539],{"trials":1105,"activeCount":8},[1106],{"nctId":565,"briefTitle":566,"status":61,"phases":1107,"primaryCompletion":212,"completion":212,"start":402,"enrollment":568,"conditions":1108,"interventions":1109},[42],[14],[549,571,536,550,500],{"trials":1111,"activeCount":8},[],{"trials":1113,"activeCount":8},[],{"intervention":550,"totalTrials":92,"cells":1115},{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1126,"PHASE4":1132,"NA":1134},{"trials":1117,"activeCount":8},[],{"trials":1119,"activeCount":8},[],{"trials":1121,"activeCount":8},[1122],{"nctId":541,"briefTitle":542,"status":61,"phases":1123,"primaryCompletion":544,"completion":545,"start":512,"enrollment":546,"conditions":1124,"interventions":1125},[41],[14],[549,518,550,500,551],{"trials":1127,"activeCount":8},[1128],{"nctId":565,"briefTitle":566,"status":61,"phases":1129,"primaryCompletion":212,"completion":212,"start":402,"enrollment":568,"conditions":1130,"interventions":1131},[42],[14],[549,571,536,550,500],{"trials":1133,"activeCount":8},[],{"trials":1135,"activeCount":8},[],{"intervention":1137,"totalTrials":92,"cells":1138},"Adjuvanted cell-derived, inactivated novel swine origin A\u002FH1N1 monovalent subunit influenza virus vaccine",{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1145,"PHASE4":1162,"NA":1164},{"trials":1140,"activeCount":8},[],{"trials":1142,"activeCount":8},[],{"trials":1144,"activeCount":8},[],{"trials":1146,"activeCount":8},[1147,1154],{"nctId":1148,"briefTitle":1149,"status":61,"phases":1150,"primaryCompletion":402,"completion":402,"start":429,"enrollment":1151,"conditions":1152,"interventions":1153},"NCT00996138","Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects",[41,42],200,[17],[1137],{"nctId":1155,"briefTitle":1156,"status":61,"phases":1157,"primaryCompletion":1158,"completion":1158,"start":401,"enrollment":1159,"conditions":1160,"interventions":1161},"NCT01000207","Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects",[41,42],"2009-12",123,[283],[1137],{"trials":1163,"activeCount":8},[],{"trials":1165,"activeCount":8},[],{"intervention":1167,"totalTrials":92,"cells":1168},"Meningococcal ACWY-CRM conjugate vaccine",{"EARLY_PHASE1":1169,"PHASE1":1171,"PHASE2":1173,"PHASE3":1175,"PHASE4":1194,"NA":1196},{"trials":1170,"activeCount":8},[],{"trials":1172,"activeCount":8},[],{"trials":1174,"activeCount":8},[],{"trials":1176,"activeCount":8},[1177,1185],{"nctId":1178,"briefTitle":1179,"status":61,"phases":1180,"primaryCompletion":378,"completion":378,"start":985,"enrollment":1181,"conditions":1182,"interventions":1183},"NCT01973218","Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.",[42],264,[14],[1184,1167],"Meningococcal B Recombinant vaccine rMenB+OMV NZ",{"nctId":1186,"briefTitle":1187,"status":61,"phases":1188,"primaryCompletion":605,"completion":605,"start":1189,"enrollment":1190,"conditions":1191,"interventions":1192},"NCT00329849","Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age",[42],"2006-05",1500,[14],[1167,1193],"Meningococcal ACWY-PS polysaccharide vaccine",{"trials":1195,"activeCount":8},[],{"trials":1197,"activeCount":8},[],{"intervention":1199,"totalTrials":92,"cells":1200},"MenACWY-CRM197",{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1215,"PHASE4":1227,"NA":1229},{"trials":1202,"activeCount":8},[],{"trials":1204,"activeCount":8},[],{"trials":1206,"activeCount":8},[1207],{"nctId":1208,"briefTitle":1209,"status":61,"phases":1210,"primaryCompletion":107,"completion":325,"start":592,"enrollment":1211,"conditions":1212,"interventions":1213},"NCT00601731","Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months",[41],382,[14],[1199,1214],"Blood test",{"trials":1216,"activeCount":8},[1217],{"nctId":1218,"briefTitle":1219,"status":61,"phases":1220,"primaryCompletion":358,"completion":237,"start":922,"enrollment":1221,"conditions":1222,"interventions":1223},"NCT00667602","Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers",[42],662,[20],[1199,1224,1225,1226,1199],"MenC","PCV7","DTPa-IPV-HepB-Hib",{"trials":1228,"activeCount":8},[],{"trials":1230,"activeCount":8},[],{"intervention":1232,"totalTrials":92,"cells":1233},"MF59-eH1N1_f",{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1238,"PHASE3":1240,"PHASE4":1258,"NA":1260},{"trials":1235,"activeCount":8},[],{"trials":1237,"activeCount":8},[],{"trials":1239,"activeCount":8},[],{"trials":1241,"activeCount":8},[1242,1249],{"nctId":1243,"briefTitle":1244,"status":61,"phases":1245,"primaryCompletion":1158,"completion":348,"start":401,"enrollment":1246,"conditions":1247,"interventions":1248},"NCT00996307","Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to \u003C36 Months",[41,42],654,[17],[1232,1232,1232,1232],{"nctId":1250,"briefTitle":1251,"status":61,"phases":1252,"primaryCompletion":401,"completion":237,"start":403,"enrollment":1253,"conditions":1254,"interventions":1256},"NCT00973700","Safety and Immunogenicity of A\u002FH1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)",[42],784,[1255],"Novel 2009 Influenza H1N1",[1232,1257],"eH1N1_f",{"trials":1259,"activeCount":8},[],{"trials":1261,"activeCount":8},[],{"intervention":1263,"totalTrials":92,"cells":1264},"MenACWY-CRM conjugate vaccine",{"EARLY_PHASE1":1265,"PHASE1":1267,"PHASE2":1269,"PHASE3":1271,"PHASE4":1293,"NA":1295},{"trials":1266,"activeCount":8},[],{"trials":1268,"activeCount":8},[],{"trials":1270,"activeCount":8},[],{"trials":1272,"activeCount":8},[1273,1283],{"nctId":1274,"briefTitle":1275,"status":61,"phases":1276,"primaryCompletion":1277,"completion":1277,"start":1278,"enrollment":1279,"conditions":1280,"interventions":1281},"NCT00856297","Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine",[42],"2012-11","2009-02",389,[20],[1263,1282],"Licensed comparator",{"nctId":1284,"briefTitle":1285,"status":61,"phases":1286,"primaryCompletion":357,"completion":357,"start":325,"enrollment":1287,"conditions":1288,"interventions":1290},"NCT01214850","Novartis Vaccine and Diagnostics Carriage Trial",[42],2968,[1289],"N. Meningitidis Carriage",[1291,1263,1292],"Meningococcal B Recombinant + Outer Membrane Vesicle vaccine","Japanese Encephalitis vaccine",{"trials":1294,"activeCount":8},[],{"trials":1296,"activeCount":8},[],{"intervention":1298,"totalTrials":127,"cells":1299},"Vaxem Hib",{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1306,"PHASE4":1316,"NA":1318},{"trials":1301,"activeCount":8},[],{"trials":1303,"activeCount":8},[],{"trials":1305,"activeCount":8},[],{"trials":1307,"activeCount":8},[1308],{"nctId":1309,"briefTitle":1310,"status":61,"phases":1311,"primaryCompletion":1158,"completion":279,"start":429,"enrollment":1312,"conditions":1313,"interventions":1314},"NCT01025544","Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China",[42],846,[842],[1298,1315],"Hiberix",{"trials":1317,"activeCount":8},[],{"trials":1319,"activeCount":8},[],{"intervention":1315,"totalTrials":127,"cells":1321},{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1328,"PHASE4":1334,"NA":1336},{"trials":1323,"activeCount":8},[],{"trials":1325,"activeCount":8},[],{"trials":1327,"activeCount":8},[],{"trials":1329,"activeCount":8},[1330],{"nctId":1309,"briefTitle":1310,"status":61,"phases":1331,"primaryCompletion":1158,"completion":279,"start":429,"enrollment":1312,"conditions":1332,"interventions":1333},[42],[842],[1298,1315],{"trials":1335,"activeCount":8},[],{"trials":1337,"activeCount":8},[],{"intervention":779,"totalTrials":127,"cells":1339},{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1344,"PHASE3":1346,"PHASE4":1352,"NA":1354},{"trials":1341,"activeCount":8},[],{"trials":1343,"activeCount":8},[],{"trials":1345,"activeCount":8},[],{"trials":1347,"activeCount":8},[1348],{"nctId":771,"briefTitle":772,"status":61,"phases":1349,"primaryCompletion":774,"completion":775,"start":528,"enrollment":776,"conditions":1350,"interventions":1351},[42],[17],[779,760],{"trials":1353,"activeCount":8},[],{"trials":1355,"activeCount":8},[],{"intervention":1357,"totalTrials":127,"cells":1358},"MF59-eH1N1",{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1363,"PHASE3":1365,"PHASE4":1374,"NA":1376},{"trials":1360,"activeCount":8},[],{"trials":1362,"activeCount":8},[],{"trials":1364,"activeCount":8},[],{"trials":1366,"activeCount":8},[1367],{"nctId":1368,"briefTitle":1369,"status":61,"phases":1370,"primaryCompletion":402,"completion":237,"start":429,"enrollment":1371,"conditions":1372,"interventions":1373},"NCT00972816","Safety and Immunogenicity of A\u002FH1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to \u003C 9 Years)",[41,42],1357,[17],[1357],{"trials":1375,"activeCount":8},[],{"trials":1377,"activeCount":8},[],{"intervention":1379,"totalTrials":127,"cells":1380},"Haemophilus influenzae type b vaccine",{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1385,"PHASE3":1387,"PHASE4":1398,"NA":1400},{"trials":1382,"activeCount":8},[],{"trials":1384,"activeCount":8},[],{"trials":1386,"activeCount":8},[],{"trials":1388,"activeCount":8},[1389],{"nctId":1390,"briefTitle":1391,"status":61,"phases":1392,"primaryCompletion":1278,"completion":1278,"start":960,"enrollment":1393,"conditions":1394,"interventions":1396},"NCT00808392","Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b",[42],916,[1395],"Haemophilus Influenzae Type b",[1379,1397],"Commercial Haemophilus influenzae type b vaccine",{"trials":1399,"activeCount":8},[],{"trials":1401,"activeCount":8},[],{"intervention":1397,"totalTrials":127,"cells":1403},{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1408,"PHASE3":1410,"PHASE4":1416,"NA":1418},{"trials":1405,"activeCount":8},[],{"trials":1407,"activeCount":8},[],{"trials":1409,"activeCount":8},[],{"trials":1411,"activeCount":8},[1412],{"nctId":1390,"briefTitle":1391,"status":61,"phases":1413,"primaryCompletion":1278,"completion":1278,"start":960,"enrollment":1393,"conditions":1414,"interventions":1415},[42],[1395],[1379,1397],{"trials":1417,"activeCount":8},[],{"trials":1419,"activeCount":8},[],{"intervention":1421,"totalTrials":127,"cells":1422},"cTIV",{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1429,"PHASE4":1438,"NA":1440},{"trials":1424,"activeCount":8},[],{"trials":1426,"activeCount":8},[],{"trials":1428,"activeCount":8},[],{"trials":1430,"activeCount":8},[1431],{"nctId":1432,"briefTitle":1433,"status":61,"phases":1434,"primaryCompletion":591,"completion":591,"start":512,"enrollment":1435,"conditions":1436,"interventions":1437},"NCT00511914","Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007\u002F2008",[42],135,[445],[1421],{"trials":1439,"activeCount":8},[],{"trials":1441,"activeCount":8},[],{"intervention":597,"totalTrials":127,"cells":1443},{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1448,"PHASE3":1450,"PHASE4":1456,"NA":1458},{"trials":1445,"activeCount":8},[],{"trials":1447,"activeCount":8},[],{"trials":1449,"activeCount":8},[],{"trials":1451,"activeCount":8},[1452],{"nctId":588,"briefTitle":589,"status":61,"phases":1453,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":1454,"interventions":1455},[42],[20,29],[597,598,577,599],{"trials":1457,"activeCount":8},[],{"trials":1459,"activeCount":8},[],{"intervention":599,"totalTrials":127,"cells":1461},{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1466,"PHASE3":1468,"PHASE4":1474,"NA":1476},{"trials":1463,"activeCount":8},[],{"trials":1465,"activeCount":8},[],{"trials":1467,"activeCount":8},[],{"trials":1469,"activeCount":8},[1470],{"nctId":588,"briefTitle":589,"status":61,"phases":1471,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":1472,"interventions":1473},[42],[20,29],[597,598,577,599],{"trials":1475,"activeCount":8},[],{"trials":1477,"activeCount":8},[],{"intervention":1479,"totalTrials":127,"cells":1480},"BEGRIVAC",{"EARLY_PHASE1":1481,"PHASE1":1483,"PHASE2":1485,"PHASE3":1487,"PHASE4":1496,"NA":1498},{"trials":1482,"activeCount":8},[],{"trials":1484,"activeCount":8},[],{"trials":1486,"activeCount":8},[],{"trials":1488,"activeCount":8},[1489],{"nctId":1490,"briefTitle":1491,"status":61,"phases":1492,"primaryCompletion":107,"completion":107,"start":370,"enrollment":1493,"conditions":1494,"interventions":1495},"NCT01147081","Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010\u002F2011",[42],142,[23],[1479],{"trials":1497,"activeCount":8},[],{"trials":1499,"activeCount":8},[],{"intervention":894,"totalTrials":127,"cells":1501},{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1508,"PHASE4":1514,"NA":1516},{"trials":1503,"activeCount":8},[],{"trials":1505,"activeCount":8},[],{"trials":1507,"activeCount":8},[],{"trials":1509,"activeCount":8},[1510],{"nctId":888,"briefTitle":889,"status":61,"phases":1511,"primaryCompletion":421,"completion":421,"start":348,"enrollment":891,"conditions":1512,"interventions":1513},[42],[14,20],[894,877],{"trials":1515,"activeCount":8},[],{"trials":1517,"activeCount":8},[],{"intervention":1519,"totalTrials":127,"cells":1520},"1a - rMenB+OMV NZ and routine vaccines",{"EARLY_PHASE1":1521,"PHASE1":1523,"PHASE2":1525,"PHASE3":1527,"PHASE4":1544,"NA":1546},{"trials":1522,"activeCount":8},[],{"trials":1524,"activeCount":8},[],{"trials":1526,"activeCount":8},[],{"trials":1528,"activeCount":8},[1529],{"nctId":1530,"briefTitle":1531,"status":61,"phases":1532,"primaryCompletion":1533,"completion":1533,"start":1278,"enrollment":1534,"conditions":1535,"interventions":1536},"NCT00847145","Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers",[42],"2010-08",2249,[14],[1519,1537,1538,1539,1540,1541,1542,1543],"1b - rMenB+OMV NZ and routine vaccines","2a - Routine and rMenB+OMV NZ vaccines","2b - rMenB+OMV NZ and routine vaccines","3a - rMenB+OMV NZ and routine vaccines","3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations","4a- rMenB+OMV NZ and routine vaccines","4b - rMenB+OMV NZ and routine vaccines",{"trials":1545,"activeCount":8},[],{"trials":1547,"activeCount":8},[],{"intervention":1537,"totalTrials":127,"cells":1549},{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1556,"PHASE4":1562,"NA":1564},{"trials":1551,"activeCount":8},[],{"trials":1553,"activeCount":8},[],{"trials":1555,"activeCount":8},[],{"trials":1557,"activeCount":8},[1558],{"nctId":1530,"briefTitle":1531,"status":61,"phases":1559,"primaryCompletion":1533,"completion":1533,"start":1278,"enrollment":1534,"conditions":1560,"interventions":1561},[42],[14],[1519,1537,1538,1539,1540,1541,1542,1543],{"trials":1563,"activeCount":8},[],{"trials":1565,"activeCount":8},[],{"intervention":1538,"totalTrials":127,"cells":1567},{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1574,"PHASE4":1580,"NA":1582},{"trials":1569,"activeCount":8},[],{"trials":1571,"activeCount":8},[],{"trials":1573,"activeCount":8},[],{"trials":1575,"activeCount":8},[1576],{"nctId":1530,"briefTitle":1531,"status":61,"phases":1577,"primaryCompletion":1533,"completion":1533,"start":1278,"enrollment":1534,"conditions":1578,"interventions":1579},[42],[14],[1519,1537,1538,1539,1540,1541,1542,1543],{"trials":1581,"activeCount":8},[],{"trials":1583,"activeCount":8},[],{"intervention":1539,"totalTrials":127,"cells":1585},{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1592,"PHASE4":1598,"NA":1600},{"trials":1587,"activeCount":8},[],{"trials":1589,"activeCount":8},[],{"trials":1591,"activeCount":8},[],{"trials":1593,"activeCount":8},[1594],{"nctId":1530,"briefTitle":1531,"status":61,"phases":1595,"primaryCompletion":1533,"completion":1533,"start":1278,"enrollment":1534,"conditions":1596,"interventions":1597},[42],[14],[1519,1537,1538,1539,1540,1541,1542,1543],{"trials":1599,"activeCount":8},[],{"trials":1601,"activeCount":8},[],{"intervention":1540,"totalTrials":127,"cells":1603},{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1610,"PHASE4":1616,"NA":1618},{"trials":1605,"activeCount":8},[],{"trials":1607,"activeCount":8},[],{"trials":1609,"activeCount":8},[],{"trials":1611,"activeCount":8},[1612],{"nctId":1530,"briefTitle":1531,"status":61,"phases":1613,"primaryCompletion":1533,"completion":1533,"start":1278,"enrollment":1534,"conditions":1614,"interventions":1615},[42],[14],[1519,1537,1538,1539,1540,1541,1542,1543],{"trials":1617,"activeCount":8},[],{"trials":1619,"activeCount":8},[],{"intervention":1541,"totalTrials":127,"cells":1621},{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1626,"PHASE3":1628,"PHASE4":1634,"NA":1636},{"trials":1623,"activeCount":8},[],{"trials":1625,"activeCount":8},[],{"trials":1627,"activeCount":8},[],{"trials":1629,"activeCount":8},[1630],{"nctId":1530,"briefTitle":1531,"status":61,"phases":1631,"primaryCompletion":1533,"completion":1533,"start":1278,"enrollment":1534,"conditions":1632,"interventions":1633},[42],[14],[1519,1537,1538,1539,1540,1541,1542,1543],{"trials":1635,"activeCount":8},[],{"trials":1637,"activeCount":8},[],{"intervention":1542,"totalTrials":127,"cells":1639},{"EARLY_PHASE1":1640,"PHASE1":1642,"PHASE2":1644,"PHASE3":1646,"PHASE4":1652,"NA":1654},{"trials":1641,"activeCount":8},[],{"trials":1643,"activeCount":8},[],{"trials":1645,"activeCount":8},[],{"trials":1647,"activeCount":8},[1648],{"nctId":1530,"briefTitle":1531,"status":61,"phases":1649,"primaryCompletion":1533,"completion":1533,"start":1278,"enrollment":1534,"conditions":1650,"interventions":1651},[42],[14],[1519,1537,1538,1539,1540,1541,1542,1543],{"trials":1653,"activeCount":8},[],{"trials":1655,"activeCount":8},[],{"intervention":1543,"totalTrials":127,"cells":1657},{"EARLY_PHASE1":1658,"PHASE1":1660,"PHASE2":1662,"PHASE3":1664,"PHASE4":1670,"NA":1672},{"trials":1659,"activeCount":8},[],{"trials":1661,"activeCount":8},[],{"trials":1663,"activeCount":8},[],{"trials":1665,"activeCount":8},[1666],{"nctId":1530,"briefTitle":1531,"status":61,"phases":1667,"primaryCompletion":1533,"completion":1533,"start":1278,"enrollment":1534,"conditions":1668,"interventions":1669},[42],[14],[1519,1537,1538,1539,1540,1541,1542,1543],{"trials":1671,"activeCount":8},[],{"trials":1673,"activeCount":8},[],{"intervention":1675,"totalTrials":127,"cells":1676},"Recombinant meningococcal B + OMV NZ",{"EARLY_PHASE1":1677,"PHASE1":1679,"PHASE2":1681,"PHASE3":1683,"PHASE4":1694,"NA":1696},{"trials":1678,"activeCount":8},[],{"trials":1680,"activeCount":8},[],{"trials":1682,"activeCount":8},[],{"trials":1684,"activeCount":8},[1685],{"nctId":1686,"briefTitle":1687,"status":61,"phases":1688,"primaryCompletion":1689,"completion":1690,"start":119,"enrollment":1691,"conditions":1692,"interventions":1693},"NCT01478347","A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults",[42],"2014-03","2014-11",18,[14,20],[1675],{"trials":1695,"activeCount":8},[],{"trials":1697,"activeCount":8},[],{"intervention":1699,"totalTrials":127,"cells":1700},"1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine",{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1707,"PHASE4":1717,"NA":1719},{"trials":1702,"activeCount":8},[],{"trials":1704,"activeCount":8},[],{"trials":1706,"activeCount":8},[],{"trials":1708,"activeCount":8},[1709],{"nctId":1710,"briefTitle":1711,"status":61,"phases":1712,"primaryCompletion":739,"completion":117,"start":1277,"enrollment":1713,"conditions":1714,"interventions":1715},"NCT01717638","Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1",[42],805,[14,20],[1699,1716],"2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine",{"trials":1718,"activeCount":8},[],{"trials":1720,"activeCount":8},[],{"intervention":1716,"totalTrials":127,"cells":1722},{"EARLY_PHASE1":1723,"PHASE1":1725,"PHASE2":1727,"PHASE3":1729,"PHASE4":1735,"NA":1737},{"trials":1724,"activeCount":8},[],{"trials":1726,"activeCount":8},[],{"trials":1728,"activeCount":8},[],{"trials":1730,"activeCount":8},[1731],{"nctId":1710,"briefTitle":1711,"status":61,"phases":1732,"primaryCompletion":739,"completion":117,"start":1277,"enrollment":1713,"conditions":1733,"interventions":1734},[42],[14,20],[1699,1716],{"trials":1736,"activeCount":8},[],{"trials":1738,"activeCount":8},[],{"intervention":927,"totalTrials":127,"cells":1740},{"EARLY_PHASE1":1741,"PHASE1":1743,"PHASE2":1745,"PHASE3":1747,"PHASE4":1753,"NA":1755},{"trials":1742,"activeCount":8},[],{"trials":1744,"activeCount":8},[],{"trials":1746,"activeCount":8},[],{"trials":1748,"activeCount":8},[1749],{"nctId":918,"briefTitle":919,"status":61,"phases":1750,"primaryCompletion":921,"completion":921,"start":922,"enrollment":923,"conditions":1751,"interventions":1752},[42],[925],[927,928,929,930,539,931],{"trials":1754,"activeCount":8},[],{"trials":1756,"activeCount":8},[],{"intervention":928,"totalTrials":127,"cells":1758},{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1763,"PHASE3":1765,"PHASE4":1771,"NA":1773},{"trials":1760,"activeCount":8},[],{"trials":1762,"activeCount":8},[],{"trials":1764,"activeCount":8},[],{"trials":1766,"activeCount":8},[1767],{"nctId":918,"briefTitle":919,"status":61,"phases":1768,"primaryCompletion":921,"completion":921,"start":922,"enrollment":923,"conditions":1769,"interventions":1770},[42],[925],[927,928,929,930,539,931],{"trials":1772,"activeCount":8},[],{"trials":1774,"activeCount":8},[],{"intervention":929,"totalTrials":127,"cells":1776},{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1783,"PHASE4":1789,"NA":1791},{"trials":1778,"activeCount":8},[],{"trials":1780,"activeCount":8},[],{"trials":1782,"activeCount":8},[],{"trials":1784,"activeCount":8},[1785],{"nctId":918,"briefTitle":919,"status":61,"phases":1786,"primaryCompletion":921,"completion":921,"start":922,"enrollment":923,"conditions":1787,"interventions":1788},[42],[925],[927,928,929,930,539,931],{"trials":1790,"activeCount":8},[],{"trials":1792,"activeCount":8},[],{"intervention":930,"totalTrials":127,"cells":1794},{"EARLY_PHASE1":1795,"PHASE1":1797,"PHASE2":1799,"PHASE3":1801,"PHASE4":1807,"NA":1809},{"trials":1796,"activeCount":8},[],{"trials":1798,"activeCount":8},[],{"trials":1800,"activeCount":8},[],{"trials":1802,"activeCount":8},[1803],{"nctId":918,"briefTitle":919,"status":61,"phases":1804,"primaryCompletion":921,"completion":921,"start":922,"enrollment":923,"conditions":1805,"interventions":1806},[42],[925],[927,928,929,930,539,931],{"trials":1808,"activeCount":8},[],{"trials":1810,"activeCount":8},[],{"intervention":931,"totalTrials":127,"cells":1812},{"EARLY_PHASE1":1813,"PHASE1":1815,"PHASE2":1817,"PHASE3":1819,"PHASE4":1825,"NA":1827},{"trials":1814,"activeCount":8},[],{"trials":1816,"activeCount":8},[],{"trials":1818,"activeCount":8},[],{"trials":1820,"activeCount":8},[1821],{"nctId":918,"briefTitle":919,"status":61,"phases":1822,"primaryCompletion":921,"completion":921,"start":922,"enrollment":923,"conditions":1823,"interventions":1824},[42],[925],[927,928,929,930,539,931],{"trials":1826,"activeCount":8},[],{"trials":1828,"activeCount":8},[],{"intervention":1830,"totalTrials":127,"cells":1831},"Zagreb",{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1836,"PHASE3":1838,"PHASE4":1850,"NA":1852},{"trials":1833,"activeCount":8},[],{"trials":1835,"activeCount":8},[],{"trials":1837,"activeCount":8},[],{"trials":1839,"activeCount":8},[1840],{"nctId":1841,"briefTitle":1842,"status":61,"phases":1843,"primaryCompletion":1844,"completion":1844,"start":1845,"enrollment":1846,"conditions":1847,"interventions":1848},"NCT01680016","A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults",[42],"2013-01","2012-09",644,[32],[1830,1849],"Essen",{"trials":1851,"activeCount":8},[],{"trials":1853,"activeCount":8},[],{"intervention":1849,"totalTrials":127,"cells":1855},{"EARLY_PHASE1":1856,"PHASE1":1858,"PHASE2":1860,"PHASE3":1862,"PHASE4":1868,"NA":1870},{"trials":1857,"activeCount":8},[],{"trials":1859,"activeCount":8},[],{"trials":1861,"activeCount":8},[],{"trials":1863,"activeCount":8},[1864],{"nctId":1841,"briefTitle":1842,"status":61,"phases":1865,"primaryCompletion":1844,"completion":1844,"start":1845,"enrollment":1846,"conditions":1866,"interventions":1867},[42],[32],[1830,1849],{"trials":1869,"activeCount":8},[],{"trials":1871,"activeCount":8},[],{"intervention":707,"totalTrials":127,"cells":1873},{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1878,"PHASE3":1880,"PHASE4":1886,"NA":1888},{"trials":1875,"activeCount":8},[],{"trials":1877,"activeCount":8},[],{"trials":1879,"activeCount":8},[],{"trials":1881,"activeCount":8},[1882],{"nctId":700,"briefTitle":701,"status":61,"phases":1883,"primaryCompletion":421,"completion":369,"start":325,"enrollment":703,"conditions":1884,"interventions":1885},[42],[23],[682,706,707],{"trials":1887,"activeCount":8},[],{"trials":1889,"activeCount":8},[],{"intervention":610,"totalTrials":127,"cells":1891},{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1896,"PHASE3":1898,"PHASE4":1904,"NA":1906},{"trials":1893,"activeCount":8},[],{"trials":1895,"activeCount":8},[],{"trials":1897,"activeCount":8},[],{"trials":1899,"activeCount":8},[1900],{"nctId":601,"briefTitle":602,"status":61,"phases":1901,"primaryCompletion":604,"completion":402,"start":605,"enrollment":606,"conditions":1902,"interventions":1903},[42],[608],[577,610,551,611,612,613,614,615],{"trials":1905,"activeCount":8},[],{"trials":1907,"activeCount":8},[],{"intervention":611,"totalTrials":127,"cells":1909},{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1914,"PHASE3":1916,"PHASE4":1922,"NA":1924},{"trials":1911,"activeCount":8},[],{"trials":1913,"activeCount":8},[],{"trials":1915,"activeCount":8},[],{"trials":1917,"activeCount":8},[1918],{"nctId":601,"briefTitle":602,"status":61,"phases":1919,"primaryCompletion":604,"completion":402,"start":605,"enrollment":606,"conditions":1920,"interventions":1921},[42],[608],[577,610,551,611,612,613,614,615],{"trials":1923,"activeCount":8},[],{"trials":1925,"activeCount":8},[],{"intervention":612,"totalTrials":127,"cells":1927},{"EARLY_PHASE1":1928,"PHASE1":1930,"PHASE2":1932,"PHASE3":1934,"PHASE4":1940,"NA":1942},{"trials":1929,"activeCount":8},[],{"trials":1931,"activeCount":8},[],{"trials":1933,"activeCount":8},[],{"trials":1935,"activeCount":8},[1936],{"nctId":601,"briefTitle":602,"status":61,"phases":1937,"primaryCompletion":604,"completion":402,"start":605,"enrollment":606,"conditions":1938,"interventions":1939},[42],[608],[577,610,551,611,612,613,614,615],{"trials":1941,"activeCount":8},[],{"trials":1943,"activeCount":8},[],{"intervention":613,"totalTrials":127,"cells":1945},{"EARLY_PHASE1":1946,"PHASE1":1948,"PHASE2":1950,"PHASE3":1952,"PHASE4":1958,"NA":1960},{"trials":1947,"activeCount":8},[],{"trials":1949,"activeCount":8},[],{"trials":1951,"activeCount":8},[],{"trials":1953,"activeCount":8},[1954],{"nctId":601,"briefTitle":602,"status":61,"phases":1955,"primaryCompletion":604,"completion":402,"start":605,"enrollment":606,"conditions":1956,"interventions":1957},[42],[608],[577,610,551,611,612,613,614,615],{"trials":1959,"activeCount":8},[],{"trials":1961,"activeCount":8},[],{"intervention":614,"totalTrials":127,"cells":1963},{"EARLY_PHASE1":1964,"PHASE1":1966,"PHASE2":1968,"PHASE3":1970,"PHASE4":1976,"NA":1978},{"trials":1965,"activeCount":8},[],{"trials":1967,"activeCount":8},[],{"trials":1969,"activeCount":8},[],{"trials":1971,"activeCount":8},[1972],{"nctId":601,"briefTitle":602,"status":61,"phases":1973,"primaryCompletion":604,"completion":402,"start":605,"enrollment":606,"conditions":1974,"interventions":1975},[42],[608],[577,610,551,611,612,613,614,615],{"trials":1977,"activeCount":8},[],{"trials":1979,"activeCount":8},[],{"intervention":615,"totalTrials":127,"cells":1981},{"EARLY_PHASE1":1982,"PHASE1":1984,"PHASE2":1986,"PHASE3":1988,"PHASE4":1994,"NA":1996},{"trials":1983,"activeCount":8},[],{"trials":1985,"activeCount":8},[],{"trials":1987,"activeCount":8},[],{"trials":1989,"activeCount":8},[1990],{"nctId":601,"briefTitle":602,"status":61,"phases":1991,"primaryCompletion":604,"completion":402,"start":605,"enrollment":606,"conditions":1992,"interventions":1993},[42],[608],[577,610,551,611,612,613,614,615],{"trials":1995,"activeCount":8},[],{"trials":1997,"activeCount":8},[],{"intervention":571,"totalTrials":127,"cells":1999},{"EARLY_PHASE1":2000,"PHASE1":2002,"PHASE2":2004,"PHASE3":2006,"PHASE4":2012,"NA":2014},{"trials":2001,"activeCount":8},[],{"trials":2003,"activeCount":8},[],{"trials":2005,"activeCount":8},[],{"trials":2007,"activeCount":8},[2008],{"nctId":565,"briefTitle":566,"status":61,"phases":2009,"primaryCompletion":212,"completion":212,"start":402,"enrollment":568,"conditions":2010,"interventions":2011},[42],[14],[549,571,536,550,500],{"trials":2013,"activeCount":8},[],{"trials":2015,"activeCount":8},[],{"intervention":2017,"totalTrials":127,"cells":2018},"Lot A of Influenza virus vaccine",{"EARLY_PHASE1":2019,"PHASE1":2021,"PHASE2":2023,"PHASE3":2025,"PHASE4":2038,"NA":2040},{"trials":2020,"activeCount":8},[],{"trials":2022,"activeCount":8},[],{"trials":2024,"activeCount":8},[],{"trials":2026,"activeCount":8},[2027],{"nctId":2028,"briefTitle":2029,"status":61,"phases":2030,"primaryCompletion":629,"completion":349,"start":169,"enrollment":2031,"conditions":2032,"interventions":2033},"NCT00617851","Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old",[42],1507,[17],[2017,2034,2035,2036,2037],"Lot B of Influenza virus vaccine","Lot C of Influenza virus vaccine","Comparator influenza virus vaccine","All 3 consecutive lots of influenza virus vaccine pooled",{"trials":2039,"activeCount":8},[],{"trials":2041,"activeCount":8},[],{"intervention":2034,"totalTrials":127,"cells":2043},{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2048,"PHASE3":2050,"PHASE4":2056,"NA":2058},{"trials":2045,"activeCount":8},[],{"trials":2047,"activeCount":8},[],{"trials":2049,"activeCount":8},[],{"trials":2051,"activeCount":8},[2052],{"nctId":2028,"briefTitle":2029,"status":61,"phases":2053,"primaryCompletion":629,"completion":349,"start":169,"enrollment":2031,"conditions":2054,"interventions":2055},[42],[17],[2017,2034,2035,2036,2037],{"trials":2057,"activeCount":8},[],{"trials":2059,"activeCount":8},[],{"intervention":2035,"totalTrials":127,"cells":2061},{"EARLY_PHASE1":2062,"PHASE1":2064,"PHASE2":2066,"PHASE3":2068,"PHASE4":2074,"NA":2076},{"trials":2063,"activeCount":8},[],{"trials":2065,"activeCount":8},[],{"trials":2067,"activeCount":8},[],{"trials":2069,"activeCount":8},[2070],{"nctId":2028,"briefTitle":2029,"status":61,"phases":2071,"primaryCompletion":629,"completion":349,"start":169,"enrollment":2031,"conditions":2072,"interventions":2073},[42],[17],[2017,2034,2035,2036,2037],{"trials":2075,"activeCount":8},[],{"trials":2077,"activeCount":8},[],{"intervention":2036,"totalTrials":127,"cells":2079},{"EARLY_PHASE1":2080,"PHASE1":2082,"PHASE2":2084,"PHASE3":2086,"PHASE4":2092,"NA":2094},{"trials":2081,"activeCount":8},[],{"trials":2083,"activeCount":8},[],{"trials":2085,"activeCount":8},[],{"trials":2087,"activeCount":8},[2088],{"nctId":2028,"briefTitle":2029,"status":61,"phases":2089,"primaryCompletion":629,"completion":349,"start":169,"enrollment":2031,"conditions":2090,"interventions":2091},[42],[17],[2017,2034,2035,2036,2037],{"trials":2093,"activeCount":8},[],{"trials":2095,"activeCount":8},[],{"intervention":2037,"totalTrials":127,"cells":2097},{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2104,"PHASE4":2110,"NA":2112},{"trials":2099,"activeCount":8},[],{"trials":2101,"activeCount":8},[],{"trials":2103,"activeCount":8},[],{"trials":2105,"activeCount":8},[2106],{"nctId":2028,"briefTitle":2029,"status":61,"phases":2107,"primaryCompletion":629,"completion":349,"start":169,"enrollment":2031,"conditions":2108,"interventions":2109},[42],[17],[2017,2034,2035,2036,2037],{"trials":2111,"activeCount":8},[],{"trials":2113,"activeCount":8},[],{"intervention":2115,"totalTrials":127,"cells":2116},"MenACWY-CRM + MMRV",{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2121,"PHASE3":2123,"PHASE4":2133,"NA":2135},{"trials":2118,"activeCount":8},[],{"trials":2120,"activeCount":8},[],{"trials":2122,"activeCount":8},[],{"trials":2124,"activeCount":8},[2125],{"nctId":2126,"briefTitle":2127,"status":61,"phases":2128,"primaryCompletion":107,"completion":237,"start":592,"enrollment":2129,"conditions":2130,"interventions":2131},"NCT00626327","Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers",[42],1630,[29],[2115,2132,549],"MMRV",{"trials":2134,"activeCount":8},[],{"trials":2136,"activeCount":8},[],{"intervention":2132,"totalTrials":127,"cells":2138},{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2145,"PHASE4":2151,"NA":2153},{"trials":2140,"activeCount":8},[],{"trials":2142,"activeCount":8},[],{"trials":2144,"activeCount":8},[],{"trials":2146,"activeCount":8},[2147],{"nctId":2126,"briefTitle":2127,"status":61,"phases":2148,"primaryCompletion":107,"completion":237,"start":592,"enrollment":2129,"conditions":2149,"interventions":2150},[42],[29],[2115,2132,549],{"trials":2152,"activeCount":8},[],{"trials":2154,"activeCount":8},[],{"intervention":788,"totalTrials":127,"cells":2156},{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2161,"PHASE3":2163,"PHASE4":2169,"NA":2171},{"trials":2158,"activeCount":8},[],{"trials":2160,"activeCount":8},[],{"trials":2162,"activeCount":8},[],{"trials":2164,"activeCount":8},[2165],{"nctId":781,"briefTitle":782,"status":61,"phases":2166,"primaryCompletion":64,"completion":76,"start":784,"enrollment":785,"conditions":2167,"interventions":2168},[42],[17],[788,789,790,791],{"trials":2170,"activeCount":8},[],{"trials":2172,"activeCount":8},[],{"intervention":789,"totalTrials":127,"cells":2174},{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2181,"PHASE4":2187,"NA":2189},{"trials":2176,"activeCount":8},[],{"trials":2178,"activeCount":8},[],{"trials":2180,"activeCount":8},[],{"trials":2182,"activeCount":8},[2183],{"nctId":781,"briefTitle":782,"status":61,"phases":2184,"primaryCompletion":64,"completion":76,"start":784,"enrollment":785,"conditions":2185,"interventions":2186},[42],[17],[788,789,790,791],{"trials":2188,"activeCount":8},[],{"trials":2190,"activeCount":8},[],{"intervention":790,"totalTrials":127,"cells":2192},{"EARLY_PHASE1":2193,"PHASE1":2195,"PHASE2":2197,"PHASE3":2199,"PHASE4":2205,"NA":2207},{"trials":2194,"activeCount":8},[],{"trials":2196,"activeCount":8},[],{"trials":2198,"activeCount":8},[],{"trials":2200,"activeCount":8},[2201],{"nctId":781,"briefTitle":782,"status":61,"phases":2202,"primaryCompletion":64,"completion":76,"start":784,"enrollment":785,"conditions":2203,"interventions":2204},[42],[17],[788,789,790,791],{"trials":2206,"activeCount":8},[],{"trials":2208,"activeCount":8},[],{"intervention":2210,"totalTrials":127,"cells":2211},"rMenB + OMV NZ vaccine",{"EARLY_PHASE1":2212,"PHASE1":2214,"PHASE2":2216,"PHASE3":2218,"PHASE4":2230,"NA":2232},{"trials":2213,"activeCount":8},[],{"trials":2215,"activeCount":8},[],{"trials":2217,"activeCount":8},[],{"trials":2219,"activeCount":8},[2220],{"nctId":2221,"briefTitle":2222,"status":61,"phases":2223,"primaryCompletion":2224,"completion":746,"start":436,"enrollment":2225,"conditions":2226,"interventions":2227},"NCT01339923","A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years",[42],"2014-01",1409,[14,20],[2210,2210,2210,2210,2228,2229,2210,2210],"Meningococcal C oligosaccharide conjugated vaccine","Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.",{"trials":2231,"activeCount":8},[],{"trials":2233,"activeCount":8},[],{"intervention":2228,"totalTrials":127,"cells":2235},{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2240,"PHASE3":2242,"PHASE4":2248,"NA":2250},{"trials":2237,"activeCount":8},[],{"trials":2239,"activeCount":8},[],{"trials":2241,"activeCount":8},[],{"trials":2243,"activeCount":8},[2244],{"nctId":2221,"briefTitle":2222,"status":61,"phases":2245,"primaryCompletion":2224,"completion":746,"start":436,"enrollment":2225,"conditions":2246,"interventions":2247},[42],[14,20],[2210,2210,2210,2210,2228,2229,2210,2210],{"trials":2249,"activeCount":8},[],{"trials":2251,"activeCount":8},[],{"intervention":2229,"totalTrials":127,"cells":2253},{"EARLY_PHASE1":2254,"PHASE1":2256,"PHASE2":2258,"PHASE3":2260,"PHASE4":2266,"NA":2268},{"trials":2255,"activeCount":8},[],{"trials":2257,"activeCount":8},[],{"trials":2259,"activeCount":8},[],{"trials":2261,"activeCount":8},[2262],{"nctId":2221,"briefTitle":2222,"status":61,"phases":2263,"primaryCompletion":2224,"completion":746,"start":436,"enrollment":2225,"conditions":2264,"interventions":2265},[42],[14,20],[2210,2210,2210,2210,2228,2229,2210,2210],{"trials":2267,"activeCount":8},[],{"trials":2269,"activeCount":8},[],{"intervention":2271,"totalTrials":127,"cells":2272},"Cell culture derived influenza vaccine",{"EARLY_PHASE1":2273,"PHASE1":2275,"PHASE2":2277,"PHASE3":2279,"PHASE4":2290,"NA":2292},{"trials":2274,"activeCount":8},[],{"trials":2276,"activeCount":8},[],{"trials":2278,"activeCount":8},[],{"trials":2280,"activeCount":8},[2281],{"nctId":2282,"briefTitle":2283,"status":61,"phases":2284,"primaryCompletion":2285,"completion":76,"start":784,"enrollment":2286,"conditions":2287,"interventions":2288},"NCT00306527","Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly",[42],"2005-12",2235,[17],[2271,2289],"egg-derived influenza subunit vaccine",{"trials":2291,"activeCount":8},[],{"trials":2293,"activeCount":8},[],{"intervention":2289,"totalTrials":127,"cells":2295},{"EARLY_PHASE1":2296,"PHASE1":2298,"PHASE2":2300,"PHASE3":2302,"PHASE4":2308,"NA":2310},{"trials":2297,"activeCount":8},[],{"trials":2299,"activeCount":8},[],{"trials":2301,"activeCount":8},[],{"trials":2303,"activeCount":8},[2304],{"nctId":2282,"briefTitle":2283,"status":61,"phases":2305,"primaryCompletion":2285,"completion":76,"start":784,"enrollment":2286,"conditions":2306,"interventions":2307},[42],[17],[2271,2289],{"trials":2309,"activeCount":8},[],{"trials":2311,"activeCount":8},[],{"intervention":2313,"totalTrials":127,"cells":2314},"Routine Vaccines",{"EARLY_PHASE1":2315,"PHASE1":2317,"PHASE2":2319,"PHASE3":2321,"PHASE4":2331,"NA":2333},{"trials":2316,"activeCount":8},[],{"trials":2318,"activeCount":8},[],{"trials":2320,"activeCount":8},[],{"trials":2322,"activeCount":8},[2323],{"nctId":2324,"briefTitle":2325,"status":61,"phases":2326,"primaryCompletion":2327,"completion":326,"start":237,"enrollment":2328,"conditions":2329,"interventions":2330},"NCT01214837","Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life",[42],"2012-04",751,[14,20],[549,549,2313],{"trials":2332,"activeCount":8},[],{"trials":2334,"activeCount":8},[],{"intervention":362,"totalTrials":127,"cells":2336},{"EARLY_PHASE1":2337,"PHASE1":2339,"PHASE2":2341,"PHASE3":2343,"PHASE4":2349,"NA":2351},{"trials":2338,"activeCount":8},[],{"trials":2340,"activeCount":8},[],{"trials":2342,"activeCount":8},[],{"trials":2344,"activeCount":8},[2345],{"nctId":354,"briefTitle":355,"status":61,"phases":2346,"primaryCompletion":144,"completion":357,"start":358,"enrollment":359,"conditions":2347,"interventions":2348},[41,42],[14,20],[362,362,313,313,362,362,363,362,363,313,363,362],{"trials":2350,"activeCount":8},[],{"trials":2352,"activeCount":8},[],{"intervention":363,"totalTrials":127,"cells":2354},{"EARLY_PHASE1":2355,"PHASE1":2357,"PHASE2":2359,"PHASE3":2361,"PHASE4":2367,"NA":2369},{"trials":2356,"activeCount":8},[],{"trials":2358,"activeCount":8},[],{"trials":2360,"activeCount":8},[],{"trials":2362,"activeCount":8},[2363],{"nctId":354,"briefTitle":355,"status":61,"phases":2364,"primaryCompletion":144,"completion":357,"start":358,"enrollment":359,"conditions":2365,"interventions":2366},[41,42],[14,20],[362,362,313,313,362,362,363,362,363,313,363,362],{"trials":2368,"activeCount":8},[],{"trials":2370,"activeCount":8},[],{"intervention":2372,"totalTrials":127,"cells":2373},"Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b",{"EARLY_PHASE1":2374,"PHASE1":2376,"PHASE2":2378,"PHASE3":2380,"PHASE4":2390,"NA":2392},{"trials":2375,"activeCount":8},[],{"trials":2377,"activeCount":8},[],{"trials":2379,"activeCount":8},[],{"trials":2381,"activeCount":8},[2382],{"nctId":2383,"briefTitle":2384,"status":61,"phases":2385,"primaryCompletion":401,"completion":279,"start":403,"enrollment":2386,"conditions":2387,"interventions":2388},"NCT01125527","Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children",[42],700,[842],[2372,2389],"Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b",{"trials":2391,"activeCount":8},[],{"trials":2393,"activeCount":8},[],{"intervention":2389,"totalTrials":127,"cells":2395},{"EARLY_PHASE1":2396,"PHASE1":2398,"PHASE2":2400,"PHASE3":2402,"PHASE4":2408,"NA":2410},{"trials":2397,"activeCount":8},[],{"trials":2399,"activeCount":8},[],{"trials":2401,"activeCount":8},[],{"trials":2403,"activeCount":8},[2404],{"nctId":2383,"briefTitle":2384,"status":61,"phases":2405,"primaryCompletion":401,"completion":279,"start":403,"enrollment":2386,"conditions":2406,"interventions":2407},[42],[842],[2372,2389],{"trials":2409,"activeCount":8},[],{"trials":2411,"activeCount":8},[],{"intervention":2413,"totalTrials":127,"cells":2414},"Tdap Vaccine",{"EARLY_PHASE1":2415,"PHASE1":2417,"PHASE2":2419,"PHASE3":2421,"PHASE4":2435,"NA":2437},{"trials":2416,"activeCount":8},[],{"trials":2418,"activeCount":8},[],{"trials":2420,"activeCount":8},[],{"trials":2422,"activeCount":8},[2423],{"nctId":2424,"briefTitle":2425,"status":61,"phases":2426,"primaryCompletion":63,"completion":2427,"start":512,"enrollment":2428,"conditions":2429,"interventions":2433},"NCT00518180","A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents",[42],"2008-10",1620,[20,2430,2431,2432],"Human Papillomavirus Infection","Pertussis","Tetanus",[2434,2413,2434],"Novartis Meningococcal ACWY Conjugate Vaccine",{"trials":2436,"activeCount":8},[],{"trials":2438,"activeCount":8},[],{"intervention":2440,"totalTrials":127,"cells":2441},"Bexsero® vaccine",{"EARLY_PHASE1":2442,"PHASE1":2444,"PHASE2":2446,"PHASE3":2448,"PHASE4":2461,"NA":2463},{"trials":2443,"activeCount":8},[],{"trials":2445,"activeCount":8},[],{"trials":2447,"activeCount":8},[],{"trials":2449,"activeCount":8},[2450],{"nctId":2451,"briefTitle":2452,"status":61,"phases":2453,"primaryCompletion":2454,"completion":2455,"start":2456,"enrollment":2457,"conditions":2458,"interventions":2460},"NCT01894919","Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28",[42],"2015-09","2015-11","2013-06",851,[2459,20],"Meningoccocal Disease",[2440,2440],{"trials":2462,"activeCount":8},[],{"trials":2464,"activeCount":8},[],{"intervention":2466,"totalTrials":127,"cells":2467},"Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects",{"EARLY_PHASE1":2468,"PHASE1":2470,"PHASE2":2472,"PHASE3":2474,"PHASE4":2485,"NA":2487},{"trials":2469,"activeCount":8},[],{"trials":2471,"activeCount":8},[],{"trials":2473,"activeCount":8},[],{"trials":2475,"activeCount":8},[2476],{"nctId":2477,"briefTitle":2478,"status":61,"phases":2479,"primaryCompletion":2480,"completion":2480,"start":236,"enrollment":2481,"conditions":2482,"interventions":2483},"NCT02255279","Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to \u003C72 Months of Age in Mexico.",[42],"2015-05",287,[17],[2466,2484],"Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).",{"trials":2486,"activeCount":8},[],{"trials":2488,"activeCount":8},[],{"intervention":2484,"totalTrials":127,"cells":2490},{"EARLY_PHASE1":2491,"PHASE1":2493,"PHASE2":2495,"PHASE3":2497,"PHASE4":2503,"NA":2505},{"trials":2492,"activeCount":8},[],{"trials":2494,"activeCount":8},[],{"trials":2496,"activeCount":8},[],{"trials":2498,"activeCount":8},[2499],{"nctId":2477,"briefTitle":2478,"status":61,"phases":2500,"primaryCompletion":2480,"completion":2480,"start":236,"enrollment":2481,"conditions":2501,"interventions":2502},[42],[17],[2466,2484],{"trials":2504,"activeCount":8},[],{"trials":2506,"activeCount":8},[],{"intervention":2508,"totalTrials":127,"cells":2509},"Cell culture-derived influenza vaccine",{"EARLY_PHASE1":2510,"PHASE1":2512,"PHASE2":2514,"PHASE3":2516,"PHASE4":2527,"NA":2529},{"trials":2511,"activeCount":8},[],{"trials":2513,"activeCount":8},[],{"trials":2515,"activeCount":8},[],{"trials":2517,"activeCount":8},[2518],{"nctId":2519,"briefTitle":2520,"status":61,"phases":2521,"primaryCompletion":168,"completion":168,"start":2522,"enrollment":2523,"conditions":2524,"interventions":2525},"NCT00630331","Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects",[42],"2007-10",11404,[17],[2508,2526],"Egg-derived influenza virus vaccine",{"trials":2528,"activeCount":8},[],{"trials":2530,"activeCount":8},[],{"intervention":2526,"totalTrials":127,"cells":2532},{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2537,"PHASE3":2539,"PHASE4":2545,"NA":2547},{"trials":2534,"activeCount":8},[],{"trials":2536,"activeCount":8},[],{"trials":2538,"activeCount":8},[],{"trials":2540,"activeCount":8},[2541],{"nctId":2519,"briefTitle":2520,"status":61,"phases":2542,"primaryCompletion":168,"completion":168,"start":2522,"enrollment":2523,"conditions":2543,"interventions":2544},[42],[17],[2508,2526],{"trials":2546,"activeCount":8},[],{"trials":2548,"activeCount":8},[],{"intervention":2550,"totalTrials":127,"cells":2551},"Adjuvanted seasonal influenza vaccine",{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2556,"PHASE3":2558,"PHASE4":2569,"NA":2571},{"trials":2553,"activeCount":8},[],{"trials":2555,"activeCount":8},[],{"trials":2557,"activeCount":8},[],{"trials":2559,"activeCount":8},[2560],{"nctId":2561,"briefTitle":2562,"status":61,"phases":2563,"primaryCompletion":2564,"completion":2565,"start":325,"enrollment":2566,"conditions":2567,"interventions":2568},"NCT01210898","Immunogenicity and Safety of V70P5 Revaccination Subjects",[42],"2011-01","2011-12",197,[17],[2550],{"trials":2570,"activeCount":8},[],{"trials":2572,"activeCount":8},[],{"intervention":752,"totalTrials":127,"cells":2574},{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2579,"PHASE3":2581,"PHASE4":2587,"NA":2589},{"trials":2576,"activeCount":8},[],{"trials":2578,"activeCount":8},[],{"trials":2580,"activeCount":8},[],{"trials":2582,"activeCount":8},[2583],{"nctId":743,"briefTitle":744,"status":61,"phases":2584,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":2585,"interventions":2586},[42],[750],[752,753,754,706],{"trials":2588,"activeCount":8},[],{"trials":2590,"activeCount":8},[],{"intervention":753,"totalTrials":127,"cells":2592},{"EARLY_PHASE1":2593,"PHASE1":2595,"PHASE2":2597,"PHASE3":2599,"PHASE4":2605,"NA":2607},{"trials":2594,"activeCount":8},[],{"trials":2596,"activeCount":8},[],{"trials":2598,"activeCount":8},[],{"trials":2600,"activeCount":8},[2601],{"nctId":743,"briefTitle":744,"status":61,"phases":2602,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":2603,"interventions":2604},[42],[750],[752,753,754,706],{"trials":2606,"activeCount":8},[],{"trials":2608,"activeCount":8},[],{"intervention":754,"totalTrials":127,"cells":2610},{"EARLY_PHASE1":2611,"PHASE1":2613,"PHASE2":2615,"PHASE3":2617,"PHASE4":2623,"NA":2625},{"trials":2612,"activeCount":8},[],{"trials":2614,"activeCount":8},[],{"trials":2616,"activeCount":8},[],{"trials":2618,"activeCount":8},[2619],{"nctId":743,"briefTitle":744,"status":61,"phases":2620,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":2621,"interventions":2622},[42],[750],[752,753,754,706],{"trials":2624,"activeCount":8},[],{"trials":2626,"activeCount":8},[],{"intervention":1184,"totalTrials":127,"cells":2628},{"EARLY_PHASE1":2629,"PHASE1":2631,"PHASE2":2633,"PHASE3":2635,"PHASE4":2641,"NA":2643},{"trials":2630,"activeCount":8},[],{"trials":2632,"activeCount":8},[],{"trials":2634,"activeCount":8},[],{"trials":2636,"activeCount":8},[2637],{"nctId":1178,"briefTitle":1179,"status":61,"phases":2638,"primaryCompletion":378,"completion":378,"start":985,"enrollment":1181,"conditions":2639,"interventions":2640},[42],[14],[1184,1167],{"trials":2642,"activeCount":8},[],{"trials":2644,"activeCount":8},[],{"intervention":2646,"totalTrials":127,"cells":2647},"Licensed meningococcal ACWY vaccine",{"EARLY_PHASE1":2648,"PHASE1":2650,"PHASE2":2652,"PHASE3":2654,"PHASE4":2664,"NA":2666},{"trials":2649,"activeCount":8},[],{"trials":2651,"activeCount":8},[],{"trials":2653,"activeCount":8},[],{"trials":2655,"activeCount":8},[2656],{"nctId":2657,"briefTitle":2658,"status":61,"phases":2659,"primaryCompletion":2660,"completion":401,"start":922,"enrollment":2661,"conditions":2662,"interventions":2663},"NCT00616421","Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children",[42],"2009-04",2907,[29],[549,549,2646],{"trials":2665,"activeCount":8},[],{"trials":2667,"activeCount":8},[],{"intervention":2669,"totalTrials":127,"cells":2670},"Combined inactivated hepatitis A & recombinant hepatitis B",{"EARLY_PHASE1":2671,"PHASE1":2673,"PHASE2":2675,"PHASE3":2677,"PHASE4":2690,"NA":2692},{"trials":2672,"activeCount":8},[],{"trials":2674,"activeCount":8},[],{"trials":2676,"activeCount":8},[],{"trials":2678,"activeCount":8},[2679],{"nctId":2680,"briefTitle":2681,"status":61,"phases":2682,"primaryCompletion":357,"completion":357,"start":304,"enrollment":2683,"conditions":2684,"interventions":2687},"NCT01453348","Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A\u002FB Vaccine With MenACWY-CRM Conjugate Vaccine",[42],252,[14,20,2685,2686],"Hepatitis A","Hepatitis B",[549,2669,2688,2689],"Recombinant hepatitis B vaccine","Inactivated hepatitis A vaccine",{"trials":2691,"activeCount":8},[],{"trials":2693,"activeCount":8},[],{"intervention":2688,"totalTrials":127,"cells":2695},{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2700,"PHASE3":2702,"PHASE4":2708,"NA":2710},{"trials":2697,"activeCount":8},[],{"trials":2699,"activeCount":8},[],{"trials":2701,"activeCount":8},[],{"trials":2703,"activeCount":8},[2704],{"nctId":2680,"briefTitle":2681,"status":61,"phases":2705,"primaryCompletion":357,"completion":357,"start":304,"enrollment":2683,"conditions":2706,"interventions":2707},[42],[14,20,2685,2686],[549,2669,2688,2689],{"trials":2709,"activeCount":8},[],{"trials":2711,"activeCount":8},[],{"intervention":2689,"totalTrials":127,"cells":2713},{"EARLY_PHASE1":2714,"PHASE1":2716,"PHASE2":2718,"PHASE3":2720,"PHASE4":2726,"NA":2728},{"trials":2715,"activeCount":8},[],{"trials":2717,"activeCount":8},[],{"trials":2719,"activeCount":8},[],{"trials":2721,"activeCount":8},[2722],{"nctId":2680,"briefTitle":2681,"status":61,"phases":2723,"primaryCompletion":357,"completion":357,"start":304,"enrollment":2683,"conditions":2724,"interventions":2725},[42],[14,20,2685,2686],[549,2669,2688,2689],{"trials":2727,"activeCount":8},[],{"trials":2729,"activeCount":8},[],{"intervention":2731,"totalTrials":127,"cells":2732},"rabies vaccine",{"EARLY_PHASE1":2733,"PHASE1":2735,"PHASE2":2737,"PHASE3":2739,"PHASE4":2750,"NA":2752},{"trials":2734,"activeCount":8},[],{"trials":2736,"activeCount":8},[],{"trials":2738,"activeCount":8},[],{"trials":2740,"activeCount":8},[2741],{"nctId":2742,"briefTitle":2743,"status":61,"phases":2744,"primaryCompletion":1189,"completion":1189,"start":2745,"enrollment":2746,"conditions":2747,"interventions":2749},"NCT00345319","Purified Rabies Vaccine for Human Use (Chick-embryo Cell)",[42],"2006-03",630,[2748],"Rabies Post-exposure Prophylaxis",[2731],{"trials":2751,"activeCount":8},[],{"trials":2753,"activeCount":8},[],{"intervention":2755,"totalTrials":127,"cells":2756},"Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010\u002F2011",{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2763,"PHASE4":2771,"NA":2773},{"trials":2758,"activeCount":8},[],{"trials":2760,"activeCount":8},[],{"trials":2762,"activeCount":8},[],{"trials":2764,"activeCount":8},[2765],{"nctId":2766,"briefTitle":2767,"status":61,"phases":2768,"primaryCompletion":107,"completion":107,"start":107,"enrollment":483,"conditions":2769,"interventions":2770},"NCT01161264","Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010\u002F2011, When Administered to Adult and Elderly Subjects",[42],[23],[2755],{"trials":2772,"activeCount":8},[],{"trials":2774,"activeCount":8},[],{"intervention":2776,"totalTrials":127,"cells":2777},"Cell derived subunit trivalent nonadjuvanted vaccine",{"EARLY_PHASE1":2778,"PHASE1":2780,"PHASE2":2782,"PHASE3":2784,"PHASE4":2792,"NA":2794},{"trials":2779,"activeCount":8},[],{"trials":2781,"activeCount":8},[],{"trials":2783,"activeCount":8},[],{"trials":2785,"activeCount":8},[2786],{"nctId":2787,"briefTitle":2788,"status":61,"phases":2789,"primaryCompletion":817,"completion":817,"start":143,"enrollment":483,"conditions":2790,"interventions":2791},"NCT01640314","Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above",[42],[17],[2776],{"trials":2793,"activeCount":8},[],{"trials":2795,"activeCount":8},[],{"intervention":32,"totalTrials":127,"cells":2797},{"EARLY_PHASE1":2798,"PHASE1":2800,"PHASE2":2802,"PHASE3":2804,"PHASE4":2815,"NA":2817},{"trials":2799,"activeCount":8},[],{"trials":2801,"activeCount":8},[],{"trials":2803,"activeCount":8},[],{"trials":2805,"activeCount":8},[2806],{"nctId":2807,"briefTitle":2808,"status":61,"phases":2809,"primaryCompletion":2810,"completion":117,"start":817,"enrollment":2811,"conditions":2812,"interventions":2814},"NCT01662440","Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects",[42],"2012-12",661,[32,2813],"Japanese Encephalitis",[32,2813],{"trials":2816,"activeCount":8},[],{"trials":2818,"activeCount":8},[],{"intervention":2813,"totalTrials":127,"cells":2820},{"EARLY_PHASE1":2821,"PHASE1":2823,"PHASE2":2825,"PHASE3":2827,"PHASE4":2833,"NA":2835},{"trials":2822,"activeCount":8},[],{"trials":2824,"activeCount":8},[],{"trials":2826,"activeCount":8},[],{"trials":2828,"activeCount":8},[2829],{"nctId":2807,"briefTitle":2808,"status":61,"phases":2830,"primaryCompletion":2810,"completion":117,"start":817,"enrollment":2811,"conditions":2831,"interventions":2832},[42],[32,2813],[32,2813],{"trials":2834,"activeCount":8},[],{"trials":2836,"activeCount":8},[],{"intervention":1282,"totalTrials":127,"cells":2838},{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2843,"PHASE3":2845,"PHASE4":2851,"NA":2853},{"trials":2840,"activeCount":8},[],{"trials":2842,"activeCount":8},[],{"trials":2844,"activeCount":8},[],{"trials":2846,"activeCount":8},[2847],{"nctId":1274,"briefTitle":1275,"status":61,"phases":2848,"primaryCompletion":1277,"completion":1277,"start":1278,"enrollment":1279,"conditions":2849,"interventions":2850},[42],[20],[1263,1282],{"trials":2852,"activeCount":8},[],{"trials":2854,"activeCount":8},[],{"intervention":1257,"totalTrials":127,"cells":2856},{"EARLY_PHASE1":2857,"PHASE1":2859,"PHASE2":2861,"PHASE3":2863,"PHASE4":2869,"NA":2871},{"trials":2858,"activeCount":8},[],{"trials":2860,"activeCount":8},[],{"trials":2862,"activeCount":8},[],{"trials":2864,"activeCount":8},[2865],{"nctId":1250,"briefTitle":1251,"status":61,"phases":2866,"primaryCompletion":401,"completion":237,"start":403,"enrollment":1253,"conditions":2867,"interventions":2868},[42],[1255],[1232,1257],{"trials":2870,"activeCount":8},[],{"trials":2872,"activeCount":8},[],{"intervention":634,"totalTrials":127,"cells":2874},{"EARLY_PHASE1":2875,"PHASE1":2877,"PHASE2":2879,"PHASE3":2881,"PHASE4":2887,"NA":2889},{"trials":2876,"activeCount":8},[],{"trials":2878,"activeCount":8},[],{"trials":2880,"activeCount":8},[],{"trials":2882,"activeCount":8},[2883],{"nctId":626,"briefTitle":627,"status":61,"phases":2884,"primaryCompletion":593,"completion":629,"start":76,"enrollment":630,"conditions":2885,"interventions":2886},[42],[14,20],[633,634,635],{"trials":2888,"activeCount":8},[],{"trials":2890,"activeCount":8},[],{"intervention":2892,"totalTrials":127,"cells":2893},"DTwP-HepB-Hib Vaccine",{"EARLY_PHASE1":2894,"PHASE1":2896,"PHASE2":2898,"PHASE3":2900,"PHASE4":2910,"NA":2912},{"trials":2895,"activeCount":8},[],{"trials":2897,"activeCount":8},[],{"trials":2899,"activeCount":8},[],{"trials":2901,"activeCount":8},[2902],{"nctId":2903,"briefTitle":2904,"status":61,"phases":2905,"primaryCompletion":2327,"completion":2327,"start":2565,"enrollment":558,"conditions":2906,"interventions":2909},"NCT01470287","Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age",[42],[2907,2432,2431,2686,2908],"Diphtheria","Hemophilus Influenzae B",[2892],{"trials":2911,"activeCount":8},[],{"trials":2913,"activeCount":8},[],{"intervention":2915,"totalTrials":127,"cells":2916},"Mammalian cell based flu vaccine",{"EARLY_PHASE1":2917,"PHASE1":2919,"PHASE2":2921,"PHASE3":2923,"PHASE4":2934,"NA":2936},{"trials":2918,"activeCount":8},[],{"trials":2920,"activeCount":8},[],{"trials":2922,"activeCount":8},[],{"trials":2924,"activeCount":8},[2925],{"nctId":2926,"briefTitle":2927,"status":61,"phases":2928,"primaryCompletion":118,"completion":118,"start":119,"enrollment":2929,"conditions":2930,"interventions":2932},"NCT01857206","Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age",[42],2055,[17,2931],"Fever",[2915,2933],"Egg based flu vaccine",{"trials":2935,"activeCount":8},[],{"trials":2937,"activeCount":8},[],{"intervention":2933,"totalTrials":127,"cells":2939},{"EARLY_PHASE1":2940,"PHASE1":2942,"PHASE2":2944,"PHASE3":2946,"PHASE4":2952,"NA":2954},{"trials":2941,"activeCount":8},[],{"trials":2943,"activeCount":8},[],{"trials":2945,"activeCount":8},[],{"trials":2947,"activeCount":8},[2948],{"nctId":2926,"briefTitle":2927,"status":61,"phases":2949,"primaryCompletion":118,"completion":118,"start":119,"enrollment":2929,"conditions":2950,"interventions":2951},[42],[17,2931],[2915,2933],{"trials":2953,"activeCount":8},[],{"trials":2955,"activeCount":8},[],{"intervention":2957,"totalTrials":127,"cells":2958},"No Vaccine",{"EARLY_PHASE1":2959,"PHASE1":2961,"PHASE2":2963,"PHASE3":2965,"PHASE4":2975,"NA":2977},{"trials":2960,"activeCount":8},[],{"trials":2962,"activeCount":8},[],{"trials":2964,"activeCount":8},[],{"trials":2966,"activeCount":8},[2967],{"nctId":2968,"briefTitle":2969,"status":61,"phases":2970,"primaryCompletion":357,"completion":357,"start":1533,"enrollment":2971,"conditions":2972,"interventions":2973},"NCT01148524","Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10",[41,42],817,[14,20],[2957,2974],"rMenB+OMV-NZ",{"trials":2976,"activeCount":8},[],{"trials":2978,"activeCount":8},[],{"intervention":2974,"totalTrials":127,"cells":2980},{"EARLY_PHASE1":2981,"PHASE1":2983,"PHASE2":2985,"PHASE3":2987,"PHASE4":2993,"NA":2995},{"trials":2982,"activeCount":8},[],{"trials":2984,"activeCount":8},[],{"trials":2986,"activeCount":8},[],{"trials":2988,"activeCount":8},[2989],{"nctId":2968,"briefTitle":2969,"status":61,"phases":2990,"primaryCompletion":357,"completion":357,"start":1533,"enrollment":2971,"conditions":2991,"interventions":2992},[41,42],[14,20],[2957,2974],{"trials":2994,"activeCount":8},[],{"trials":2996,"activeCount":8},[],{"intervention":1291,"totalTrials":127,"cells":2998},{"EARLY_PHASE1":2999,"PHASE1":3001,"PHASE2":3003,"PHASE3":3005,"PHASE4":3011,"NA":3013},{"trials":3000,"activeCount":8},[],{"trials":3002,"activeCount":8},[],{"trials":3004,"activeCount":8},[],{"trials":3006,"activeCount":8},[3007],{"nctId":1284,"briefTitle":1285,"status":61,"phases":3008,"primaryCompletion":357,"completion":357,"start":325,"enrollment":1287,"conditions":3009,"interventions":3010},[42],[1289],[1291,1263,1292],{"trials":3012,"activeCount":8},[],{"trials":3014,"activeCount":8},[],{"intervention":1292,"totalTrials":127,"cells":3016},{"EARLY_PHASE1":3017,"PHASE1":3019,"PHASE2":3021,"PHASE3":3023,"PHASE4":3029,"NA":3031},{"trials":3018,"activeCount":8},[],{"trials":3020,"activeCount":8},[],{"trials":3022,"activeCount":8},[],{"trials":3024,"activeCount":8},[3025],{"nctId":1284,"briefTitle":1285,"status":61,"phases":3026,"primaryCompletion":357,"completion":357,"start":325,"enrollment":1287,"conditions":3027,"interventions":3028},[42],[1289],[1291,1263,1292],{"trials":3030,"activeCount":8},[],{"trials":3032,"activeCount":8},[],{"intervention":3034,"totalTrials":127,"cells":3035},"Trivalent split influenza vaccine",{"EARLY_PHASE1":3036,"PHASE1":3038,"PHASE2":3040,"PHASE3":3042,"PHASE4":3053,"NA":3055},{"trials":3037,"activeCount":8},[],{"trials":3039,"activeCount":8},[],{"trials":3041,"activeCount":8},[],{"trials":3043,"activeCount":8},[3044],{"nctId":3045,"briefTitle":3046,"status":61,"phases":3047,"primaryCompletion":143,"completion":143,"start":436,"enrollment":3048,"conditions":3049,"interventions":3050},"NCT01346592","Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to \u003C 72 Months of Age",[42],6104,[665],[3034,3051,3052],"MF59-adjuvanted trivalent influenza vaccine","Licensed comparator trivalent split influenza vaccine",{"trials":3054,"activeCount":8},[],{"trials":3056,"activeCount":8},[],{"intervention":3051,"totalTrials":127,"cells":3058},{"EARLY_PHASE1":3059,"PHASE1":3061,"PHASE2":3063,"PHASE3":3065,"PHASE4":3071,"NA":3073},{"trials":3060,"activeCount":8},[],{"trials":3062,"activeCount":8},[],{"trials":3064,"activeCount":8},[],{"trials":3066,"activeCount":8},[3067],{"nctId":3045,"briefTitle":3046,"status":61,"phases":3068,"primaryCompletion":143,"completion":143,"start":436,"enrollment":3048,"conditions":3069,"interventions":3070},[42],[665],[3034,3051,3052],{"trials":3072,"activeCount":8},[],{"trials":3074,"activeCount":8},[],{"intervention":3052,"totalTrials":127,"cells":3076},{"EARLY_PHASE1":3077,"PHASE1":3079,"PHASE2":3081,"PHASE3":3083,"PHASE4":3089,"NA":3091},{"trials":3078,"activeCount":8},[],{"trials":3080,"activeCount":8},[],{"trials":3082,"activeCount":8},[],{"trials":3084,"activeCount":8},[3085],{"nctId":3045,"briefTitle":3046,"status":61,"phases":3086,"primaryCompletion":143,"completion":143,"start":436,"enrollment":3048,"conditions":3087,"interventions":3088},[42],[665],[3034,3051,3052],{"trials":3090,"activeCount":8},[],{"trials":3092,"activeCount":8},[],{"intervention":3094,"totalTrials":127,"cells":3095},"Abbreviated Zagreb 2-1-1 schedule",{"EARLY_PHASE1":3096,"PHASE1":3098,"PHASE2":3100,"PHASE3":3102,"PHASE4":3113,"NA":3115},{"trials":3097,"activeCount":8},[],{"trials":3099,"activeCount":8},[],{"trials":3101,"activeCount":8},[],{"trials":3103,"activeCount":8},[3104],{"nctId":3105,"briefTitle":3106,"status":61,"phases":3107,"primaryCompletion":949,"completion":3108,"start":960,"enrollment":3109,"conditions":3110,"interventions":3111},"NCT00825305","Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)",[42],"2009-01",825,[32],[3094,3112],"Standard Essen 1-1-1-1-1 schedule",{"trials":3114,"activeCount":8},[],{"trials":3116,"activeCount":8},[],{"intervention":3112,"totalTrials":127,"cells":3118},{"EARLY_PHASE1":3119,"PHASE1":3121,"PHASE2":3123,"PHASE3":3125,"PHASE4":3131,"NA":3133},{"trials":3120,"activeCount":8},[],{"trials":3122,"activeCount":8},[],{"trials":3124,"activeCount":8},[],{"trials":3126,"activeCount":8},[3127],{"nctId":3105,"briefTitle":3106,"status":61,"phases":3128,"primaryCompletion":949,"completion":3108,"start":960,"enrollment":3109,"conditions":3129,"interventions":3130},[42],[32],[3094,3112],{"trials":3132,"activeCount":8},[],{"trials":3134,"activeCount":8},[],{"intervention":1193,"totalTrials":127,"cells":3136},{"EARLY_PHASE1":3137,"PHASE1":3139,"PHASE2":3141,"PHASE3":3143,"PHASE4":3149,"NA":3151},{"trials":3138,"activeCount":8},[],{"trials":3140,"activeCount":8},[],{"trials":3142,"activeCount":8},[],{"trials":3144,"activeCount":8},[3145],{"nctId":1186,"briefTitle":1187,"status":61,"phases":3146,"primaryCompletion":605,"completion":605,"start":1189,"enrollment":1190,"conditions":3147,"interventions":3148},[42],[14],[1167,1193],{"trials":3150,"activeCount":8},[],{"trials":3152,"activeCount":8},[],{"intervention":3154,"totalTrials":127,"cells":3155},"MF59 adjuvanted trivalent subunit influenza vaccine",{"EARLY_PHASE1":3156,"PHASE1":3158,"PHASE2":3160,"PHASE3":3162,"PHASE4":3172,"NA":3174},{"trials":3157,"activeCount":8},[],{"trials":3159,"activeCount":8},[],{"trials":3161,"activeCount":8},[],{"trials":3163,"activeCount":8},[3164],{"nctId":3165,"briefTitle":3166,"status":61,"phases":3167,"primaryCompletion":144,"completion":212,"start":1533,"enrollment":3168,"conditions":3169,"interventions":3170},"NCT01162122","Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects",[42],7109,[17],[3154,3171],"Non-adjuvanted trivalent subunit influenza vaccine",{"trials":3173,"activeCount":8},[],{"trials":3175,"activeCount":8},[],{"intervention":3171,"totalTrials":127,"cells":3177},{"EARLY_PHASE1":3178,"PHASE1":3180,"PHASE2":3182,"PHASE3":3184,"PHASE4":3190,"NA":3192},{"trials":3179,"activeCount":8},[],{"trials":3181,"activeCount":8},[],{"trials":3183,"activeCount":8},[],{"trials":3185,"activeCount":8},[3186],{"nctId":3165,"briefTitle":3166,"status":61,"phases":3187,"primaryCompletion":144,"completion":212,"start":1533,"enrollment":3168,"conditions":3188,"interventions":3189},[42],[17],[3154,3171],{"trials":3191,"activeCount":8},[],{"trials":3193,"activeCount":8},[],{"intervention":1224,"totalTrials":127,"cells":3195},{"EARLY_PHASE1":3196,"PHASE1":3198,"PHASE2":3200,"PHASE3":3202,"PHASE4":3208,"NA":3210},{"trials":3197,"activeCount":8},[],{"trials":3199,"activeCount":8},[],{"trials":3201,"activeCount":8},[],{"trials":3203,"activeCount":8},[3204],{"nctId":1218,"briefTitle":1219,"status":61,"phases":3205,"primaryCompletion":358,"completion":237,"start":922,"enrollment":1221,"conditions":3206,"interventions":3207},[42],[20],[1199,1224,1225,1226,1199],{"trials":3209,"activeCount":8},[],{"trials":3211,"activeCount":8},[],{"intervention":1225,"totalTrials":127,"cells":3213},{"EARLY_PHASE1":3214,"PHASE1":3216,"PHASE2":3218,"PHASE3":3220,"PHASE4":3226,"NA":3228},{"trials":3215,"activeCount":8},[],{"trials":3217,"activeCount":8},[],{"trials":3219,"activeCount":8},[],{"trials":3221,"activeCount":8},[3222],{"nctId":1218,"briefTitle":1219,"status":61,"phases":3223,"primaryCompletion":358,"completion":237,"start":922,"enrollment":1221,"conditions":3224,"interventions":3225},[42],[20],[1199,1224,1225,1226,1199],{"trials":3227,"activeCount":8},[],{"trials":3229,"activeCount":8},[],{"intervention":1226,"totalTrials":127,"cells":3231},{"EARLY_PHASE1":3232,"PHASE1":3234,"PHASE2":3236,"PHASE3":3238,"PHASE4":3244,"NA":3246},{"trials":3233,"activeCount":8},[],{"trials":3235,"activeCount":8},[],{"trials":3237,"activeCount":8},[],{"trials":3239,"activeCount":8},[3240],{"nctId":1218,"briefTitle":1219,"status":61,"phases":3241,"primaryCompletion":358,"completion":237,"start":922,"enrollment":1221,"conditions":3242,"interventions":3243},[42],[20],[1199,1224,1225,1226,1199],{"trials":3245,"activeCount":8},[],{"trials":3247,"activeCount":8},[],{"intervention":3249,"totalTrials":127,"cells":3250},"Hib-CRM197",{"EARLY_PHASE1":3251,"PHASE1":3253,"PHASE2":3255,"PHASE3":3257,"PHASE4":3269,"NA":3271},{"trials":3252,"activeCount":8},[],{"trials":3254,"activeCount":8},[],{"trials":3256,"activeCount":8},[],{"trials":3258,"activeCount":8},[3259],{"nctId":3260,"briefTitle":3261,"status":61,"phases":3262,"primaryCompletion":746,"completion":3263,"start":1690,"enrollment":3264,"conditions":3265,"interventions":3267},"NCT02139228","Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children",[42],"2015-01",426,[3266],"Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b",[3249,3268],"Hib-TT",{"trials":3270,"activeCount":8},[],{"trials":3272,"activeCount":8},[],{"intervention":3268,"totalTrials":127,"cells":3274},{"EARLY_PHASE1":3275,"PHASE1":3277,"PHASE2":3279,"PHASE3":3281,"PHASE4":3287,"NA":3289},{"trials":3276,"activeCount":8},[],{"trials":3278,"activeCount":8},[],{"trials":3280,"activeCount":8},[],{"trials":3282,"activeCount":8},[3283],{"nctId":3260,"briefTitle":3261,"status":61,"phases":3284,"primaryCompletion":746,"completion":3263,"start":1690,"enrollment":3264,"conditions":3285,"interventions":3286},[42],[3266],[3249,3268],{"trials":3288,"activeCount":8},[],{"trials":3290,"activeCount":8},[],{"intervention":331,"totalTrials":48,"cells":3292},{"EARLY_PHASE1":3293,"PHASE1":3295,"PHASE2":3297,"PHASE3":3315,"PHASE4":3317,"NA":3319},{"trials":3294,"activeCount":8},[],{"trials":3296,"activeCount":8},[],{"trials":3298,"activeCount":8},[3299,3303,3307],{"nctId":322,"briefTitle":323,"status":61,"phases":3300,"primaryCompletion":325,"completion":326,"start":327,"enrollment":328,"conditions":3301,"interventions":3302},[41],[14],[331,313],{"nctId":509,"briefTitle":510,"status":61,"phases":3304,"primaryCompletion":512,"completion":336,"start":305,"enrollment":513,"conditions":3305,"interventions":3306},[41],[515],[331,517,518,519,520,521,500],{"nctId":3308,"briefTitle":3309,"status":61,"phases":3310,"primaryCompletion":629,"completion":168,"start":3311,"enrollment":3312,"conditions":3313,"interventions":3314},"NCT00433914","Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants",[41],"2007-02",60,[14],[331,517],{"trials":3316,"activeCount":8},[],{"trials":3318,"activeCount":8},[],{"trials":3320,"activeCount":8},[],{"intervention":3322,"totalTrials":48,"cells":3323},"Influenza vaccine",{"EARLY_PHASE1":3324,"PHASE1":3326,"PHASE2":3332,"PHASE3":3348,"PHASE4":3350,"NA":3352},{"trials":3325,"activeCount":8},[],{"trials":3327,"activeCount":8},[3328],{"nctId":648,"briefTitle":649,"status":61,"phases":3329,"primaryCompletion":336,"completion":336,"start":349,"enrollment":651,"conditions":3330,"interventions":3331},[40],[17],[654,655],{"trials":3333,"activeCount":8},[3334,3341],{"nctId":3335,"briefTitle":3336,"status":61,"phases":3337,"primaryCompletion":358,"completion":358,"start":545,"enrollment":3338,"conditions":3339,"interventions":3340},"NCT00918268","Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009\u002F2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly Subjects",[41],130,[665],[3322],{"nctId":3342,"briefTitle":3343,"status":61,"phases":3344,"primaryCompletion":591,"completion":591,"start":556,"enrollment":3345,"conditions":3346,"interventions":3347},"NCT00408395","Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children",[41],281,[17],[3322],{"trials":3349,"activeCount":8},[],{"trials":3351,"activeCount":8},[],{"trials":3353,"activeCount":8},[],{"intervention":3355,"totalTrials":48,"cells":3356},"Adjuvanted H5N1 pandemic influenza vaccine",{"EARLY_PHASE1":3357,"PHASE1":3359,"PHASE2":3361,"PHASE3":3385,"PHASE4":3387,"NA":3389},{"trials":3358,"activeCount":8},[],{"trials":3360,"activeCount":8},[],{"trials":3362,"activeCount":8},[3363,3370,3378],{"nctId":3364,"briefTitle":3365,"status":61,"phases":3366,"primaryCompletion":2456,"completion":118,"start":1844,"enrollment":1221,"conditions":3367,"interventions":3369},"NCT01776554","Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children",[41],[3368],"Pandemic H5N1 Influenza",[3355],{"nctId":3371,"briefTitle":3372,"status":61,"phases":3373,"primaryCompletion":2456,"completion":3374,"start":1844,"enrollment":3375,"conditions":3376,"interventions":3377},"NCT01776541","Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults",[41],"2014-05",979,[3368],[3355],{"nctId":3379,"briefTitle":3380,"status":61,"phases":3381,"primaryCompletion":694,"completion":712,"start":1844,"enrollment":3382,"conditions":3383,"interventions":3384},"NCT01766921","Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects",[41],1393,[3368],[3355],{"trials":3386,"activeCount":8},[],{"trials":3388,"activeCount":8},[],{"trials":3390,"activeCount":8},[],{"intervention":518,"totalTrials":48,"cells":3392},{"EARLY_PHASE1":3393,"PHASE1":3395,"PHASE2":3397,"PHASE3":3411,"PHASE4":3413,"NA":3415},{"trials":3394,"activeCount":8},[],{"trials":3396,"activeCount":8},[],{"trials":3398,"activeCount":8},[3399,3403,3407],{"nctId":509,"briefTitle":510,"status":61,"phases":3400,"primaryCompletion":512,"completion":336,"start":305,"enrollment":513,"conditions":3401,"interventions":3402},[41],[515],[331,517,518,519,520,521,500],{"nctId":541,"briefTitle":542,"status":61,"phases":3404,"primaryCompletion":544,"completion":545,"start":512,"enrollment":546,"conditions":3405,"interventions":3406},[41],[14],[549,518,550,500,551],{"nctId":553,"briefTitle":554,"status":61,"phases":3408,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":3409,"interventions":3410},[41],[20],[549,520,518,519,500,561],{"trials":3412,"activeCount":8},[],{"trials":3414,"activeCount":8},[],{"trials":3416,"activeCount":8},[],{"intervention":3418,"totalTrials":92,"cells":3419},"Seasonal flu vaccine",{"EARLY_PHASE1":3420,"PHASE1":3422,"PHASE2":3424,"PHASE3":3438,"PHASE4":3440,"NA":3442},{"trials":3421,"activeCount":8},[],{"trials":3423,"activeCount":8},[],{"trials":3425,"activeCount":8},[3426,3432],{"nctId":3427,"briefTitle":3428,"status":61,"phases":3429,"primaryCompletion":280,"completion":279,"start":921,"enrollment":77,"conditions":3430,"interventions":3431},"NCT01123954","Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers",[41],[23],[3418],{"nctId":3433,"briefTitle":3434,"status":61,"phases":3435,"primaryCompletion":370,"completion":107,"start":370,"enrollment":473,"conditions":3436,"interventions":3437},"NCT01152814","Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011",[41],[23],[3418],{"trials":3439,"activeCount":8},[],{"trials":3441,"activeCount":8},[],{"trials":3443,"activeCount":8},[],{"intervention":517,"totalTrials":92,"cells":3445},{"EARLY_PHASE1":3446,"PHASE1":3448,"PHASE2":3450,"PHASE3":3460,"PHASE4":3462,"NA":3464},{"trials":3447,"activeCount":8},[],{"trials":3449,"activeCount":8},[],{"trials":3451,"activeCount":8},[3452,3456],{"nctId":509,"briefTitle":510,"status":61,"phases":3453,"primaryCompletion":512,"completion":336,"start":305,"enrollment":513,"conditions":3454,"interventions":3455},[41],[515],[331,517,518,519,520,521,500],{"nctId":3308,"briefTitle":3309,"status":61,"phases":3457,"primaryCompletion":629,"completion":168,"start":3311,"enrollment":3312,"conditions":3458,"interventions":3459},[41],[14],[331,517],{"trials":3461,"activeCount":8},[],{"trials":3463,"activeCount":8},[],{"trials":3465,"activeCount":8},[],{"intervention":519,"totalTrials":92,"cells":3467},{"EARLY_PHASE1":3468,"PHASE1":3470,"PHASE2":3472,"PHASE3":3482,"PHASE4":3484,"NA":3486},{"trials":3469,"activeCount":8},[],{"trials":3471,"activeCount":8},[],{"trials":3473,"activeCount":8},[3474,3478],{"nctId":509,"briefTitle":510,"status":61,"phases":3475,"primaryCompletion":512,"completion":336,"start":305,"enrollment":513,"conditions":3476,"interventions":3477},[41],[515],[331,517,518,519,520,521,500],{"nctId":553,"briefTitle":554,"status":61,"phases":3479,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":3480,"interventions":3481},[41],[20],[549,520,518,519,500,561],{"trials":3483,"activeCount":8},[],{"trials":3485,"activeCount":8},[],{"trials":3487,"activeCount":8},[],{"intervention":520,"totalTrials":92,"cells":3489},{"EARLY_PHASE1":3490,"PHASE1":3492,"PHASE2":3494,"PHASE3":3504,"PHASE4":3506,"NA":3508},{"trials":3491,"activeCount":8},[],{"trials":3493,"activeCount":8},[],{"trials":3495,"activeCount":8},[3496,3500],{"nctId":509,"briefTitle":510,"status":61,"phases":3497,"primaryCompletion":512,"completion":336,"start":305,"enrollment":513,"conditions":3498,"interventions":3499},[41],[515],[331,517,518,519,520,521,500],{"nctId":553,"briefTitle":554,"status":61,"phases":3501,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":3502,"interventions":3503},[41],[20],[549,520,518,519,500,561],{"trials":3505,"activeCount":8},[],{"trials":3507,"activeCount":8},[],{"trials":3509,"activeCount":8},[],{"intervention":3511,"totalTrials":92,"cells":3512},"MenACWY-CRM conjugate vaccine, adjuvanted",{"EARLY_PHASE1":3513,"PHASE1":3515,"PHASE2":3517,"PHASE3":3537,"PHASE4":3539,"NA":3541},{"trials":3514,"activeCount":8},[],{"trials":3516,"activeCount":8},[],{"trials":3518,"activeCount":8},[3519,3529],{"nctId":3520,"briefTitle":3521,"status":61,"phases":3522,"primaryCompletion":2745,"completion":2745,"start":3523,"enrollment":3524,"conditions":3525,"interventions":3526},"NCT00262041","Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents",[41],"2004-10",524,[531],[3511,3527,3528],"MenACWY-CRM conjugate vaccine, unadjuvanted","MenACWY polysaccharide vaccine",{"nctId":3530,"briefTitle":3531,"status":61,"phases":3532,"primaryCompletion":1189,"completion":1189,"start":3533,"enrollment":3534,"conditions":3535,"interventions":3536},"NCT00310817","Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.",[41],"2005-03",623,[20],[3511,3528,3527],{"trials":3538,"activeCount":8},[],{"trials":3540,"activeCount":8},[],{"trials":3542,"activeCount":8},[],{"intervention":3527,"totalTrials":92,"cells":3544},{"EARLY_PHASE1":3545,"PHASE1":3547,"PHASE2":3549,"PHASE3":3559,"PHASE4":3561,"NA":3563},{"trials":3546,"activeCount":8},[],{"trials":3548,"activeCount":8},[],{"trials":3550,"activeCount":8},[3551,3555],{"nctId":3520,"briefTitle":3521,"status":61,"phases":3552,"primaryCompletion":2745,"completion":2745,"start":3523,"enrollment":3524,"conditions":3553,"interventions":3554},[41],[531],[3511,3527,3528],{"nctId":3530,"briefTitle":3531,"status":61,"phases":3556,"primaryCompletion":1189,"completion":1189,"start":3533,"enrollment":3534,"conditions":3557,"interventions":3558},[41],[20],[3511,3528,3527],{"trials":3560,"activeCount":8},[],{"trials":3562,"activeCount":8},[],{"trials":3564,"activeCount":8},[],{"intervention":3528,"totalTrials":92,"cells":3566},{"EARLY_PHASE1":3567,"PHASE1":3569,"PHASE2":3571,"PHASE3":3581,"PHASE4":3583,"NA":3585},{"trials":3568,"activeCount":8},[],{"trials":3570,"activeCount":8},[],{"trials":3572,"activeCount":8},[3573,3577],{"nctId":3520,"briefTitle":3521,"status":61,"phases":3574,"primaryCompletion":2745,"completion":2745,"start":3523,"enrollment":3524,"conditions":3575,"interventions":3576},[41],[531],[3511,3527,3528],{"nctId":3530,"briefTitle":3531,"status":61,"phases":3578,"primaryCompletion":1189,"completion":1189,"start":3533,"enrollment":3534,"conditions":3579,"interventions":3580},[41],[20],[3511,3528,3527],{"trials":3582,"activeCount":8},[],{"trials":3584,"activeCount":8},[],{"trials":3586,"activeCount":8},[],{"intervention":3588,"totalTrials":92,"cells":3589},"H5N1 Influenza Vaccine",{"EARLY_PHASE1":3590,"PHASE1":3592,"PHASE2":3594,"PHASE3":3615,"PHASE4":3617,"NA":3619},{"trials":3591,"activeCount":8},[],{"trials":3593,"activeCount":8},[],{"trials":3595,"activeCount":8},[3596,3606],{"nctId":3597,"briefTitle":3598,"status":61,"phases":3599,"primaryCompletion":2522,"completion":3600,"start":3601,"enrollment":3602,"conditions":3603,"interventions":3605},"NCT00537524","Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years",[41],"2008-05","2007-09",471,[3604],"Prophylaxis of Avian Influenza",[3588,3588],{"nctId":3607,"briefTitle":3608,"status":61,"phases":3609,"primaryCompletion":629,"completion":349,"start":2522,"enrollment":3610,"conditions":3611,"interventions":3613},"NCT00561184","Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine",[41],47,[3612],"Avian Influenza",[3614,3614],"H5N1 influenza vaccine",{"trials":3616,"activeCount":8},[],{"trials":3618,"activeCount":8},[],{"trials":3620,"activeCount":8},[],{"intervention":3622,"totalTrials":127,"cells":3623},"Meningococcal Vaccine",{"EARLY_PHASE1":3624,"PHASE1":3626,"PHASE2":3628,"PHASE3":3637,"PHASE4":3639,"NA":3641},{"trials":3625,"activeCount":8},[],{"trials":3627,"activeCount":8},[],{"trials":3629,"activeCount":8},[3630],{"nctId":3631,"briefTitle":3632,"status":61,"phases":3633,"primaryCompletion":213,"completion":213,"start":348,"enrollment":3634,"conditions":3635,"interventions":3636},"NCT01210885","Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents",[41],495,[14,20],[3622],{"trials":3638,"activeCount":8},[],{"trials":3640,"activeCount":8},[],{"trials":3642,"activeCount":8},[],{"intervention":3644,"totalTrials":127,"cells":3645},"Meningococcal B vaccine",{"EARLY_PHASE1":3646,"PHASE1":3648,"PHASE2":3650,"PHASE3":3661,"PHASE4":3663,"NA":3665},{"trials":3647,"activeCount":8},[],{"trials":3649,"activeCount":8},[],{"trials":3651,"activeCount":8},[3652],{"nctId":3653,"briefTitle":3654,"status":61,"phases":3655,"primaryCompletion":368,"completion":3656,"start":358,"enrollment":2031,"conditions":3657,"interventions":3658},"NCT00937521","Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants",[41],"2012-02",[20,29],[3644,3644,3644,3644,3644,3644,3659,3660],"Control","Meningococcal B vaccine with antipyretic",{"trials":3662,"activeCount":8},[],{"trials":3664,"activeCount":8},[],{"trials":3666,"activeCount":8},[],{"intervention":3659,"totalTrials":127,"cells":3668},{"EARLY_PHASE1":3669,"PHASE1":3671,"PHASE2":3673,"PHASE3":3679,"PHASE4":3681,"NA":3683},{"trials":3670,"activeCount":8},[],{"trials":3672,"activeCount":8},[],{"trials":3674,"activeCount":8},[3675],{"nctId":3653,"briefTitle":3654,"status":61,"phases":3676,"primaryCompletion":368,"completion":3656,"start":358,"enrollment":2031,"conditions":3677,"interventions":3678},[41],[20,29],[3644,3644,3644,3644,3644,3644,3659,3660],{"trials":3680,"activeCount":8},[],{"trials":3682,"activeCount":8},[],{"trials":3684,"activeCount":8},[],{"intervention":3660,"totalTrials":127,"cells":3686},{"EARLY_PHASE1":3687,"PHASE1":3689,"PHASE2":3691,"PHASE3":3697,"PHASE4":3699,"NA":3701},{"trials":3688,"activeCount":8},[],{"trials":3690,"activeCount":8},[],{"trials":3692,"activeCount":8},[3693],{"nctId":3653,"briefTitle":3654,"status":61,"phases":3694,"primaryCompletion":368,"completion":3656,"start":358,"enrollment":2031,"conditions":3695,"interventions":3696},[41],[20,29],[3644,3644,3644,3644,3644,3644,3659,3660],{"trials":3698,"activeCount":8},[],{"trials":3700,"activeCount":8},[],{"trials":3702,"activeCount":8},[],{"intervention":3704,"totalTrials":127,"cells":3705},"Men ACWY CRM",{"EARLY_PHASE1":3706,"PHASE1":3708,"PHASE2":3710,"PHASE3":3720,"PHASE4":3722,"NA":3724},{"trials":3707,"activeCount":8},[],{"trials":3709,"activeCount":8},[],{"trials":3711,"activeCount":8},[3712],{"nctId":3713,"briefTitle":3714,"status":61,"phases":3715,"primaryCompletion":402,"completion":402,"start":512,"enrollment":3716,"conditions":3717,"interventions":3718},"NCT00560313","Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults",[41],54,[14],[3704,3719],"4CMenB",{"trials":3721,"activeCount":8},[],{"trials":3723,"activeCount":8},[],{"trials":3725,"activeCount":8},[],{"intervention":3719,"totalTrials":127,"cells":3727},{"EARLY_PHASE1":3728,"PHASE1":3730,"PHASE2":3732,"PHASE3":3738,"PHASE4":3740,"NA":3742},{"trials":3729,"activeCount":8},[],{"trials":3731,"activeCount":8},[],{"trials":3733,"activeCount":8},[3734],{"nctId":3713,"briefTitle":3714,"status":61,"phases":3735,"primaryCompletion":402,"completion":402,"start":512,"enrollment":3716,"conditions":3736,"interventions":3737},[41],[14],[3704,3719],{"trials":3739,"activeCount":8},[],{"trials":3741,"activeCount":8},[],{"trials":3743,"activeCount":8},[],{"intervention":3745,"totalTrials":127,"cells":3746},"MenABCWY+OMV",{"EARLY_PHASE1":3747,"PHASE1":3749,"PHASE2":3751,"PHASE3":3763,"PHASE4":3765,"NA":3767},{"trials":3748,"activeCount":8},[],{"trials":3750,"activeCount":8},[],{"trials":3752,"activeCount":8},[3753],{"nctId":3754,"briefTitle":3755,"status":61,"phases":3756,"primaryCompletion":3374,"completion":3757,"start":3758,"enrollment":3759,"conditions":3760,"interventions":3761},"NCT01992536","Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)",[41],"2015-04","2013-12",194,[14],[3745,3762],"MenABCWY+¼OMV",{"trials":3764,"activeCount":8},[],{"trials":3766,"activeCount":8},[],{"trials":3768,"activeCount":8},[],{"intervention":3762,"totalTrials":127,"cells":3770},{"EARLY_PHASE1":3771,"PHASE1":3773,"PHASE2":3775,"PHASE3":3781,"PHASE4":3783,"NA":3785},{"trials":3772,"activeCount":8},[],{"trials":3774,"activeCount":8},[],{"trials":3776,"activeCount":8},[3777],{"nctId":3754,"briefTitle":3755,"status":61,"phases":3778,"primaryCompletion":3374,"completion":3757,"start":3758,"enrollment":3759,"conditions":3779,"interventions":3780},[41],[14],[3745,3762],{"trials":3782,"activeCount":8},[],{"trials":3784,"activeCount":8},[],{"trials":3786,"activeCount":8},[],{"intervention":3788,"totalTrials":127,"cells":3789},"Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008",{"EARLY_PHASE1":3790,"PHASE1":3792,"PHASE2":3794,"PHASE3":3803,"PHASE4":3805,"NA":3807},{"trials":3791,"activeCount":8},[],{"trials":3793,"activeCount":8},[],{"trials":3795,"activeCount":8},[3796],{"nctId":3797,"briefTitle":3798,"status":61,"phases":3799,"primaryCompletion":512,"completion":512,"start":662,"enrollment":3800,"conditions":3801,"interventions":3802},"NCT00522236","Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007\u002F2008) When Administered to Elderly Subjects",[41],56,[17],[3788],{"trials":3804,"activeCount":8},[],{"trials":3806,"activeCount":8},[],{"trials":3808,"activeCount":8},[],{"intervention":3810,"totalTrials":127,"cells":3811},"Trivalent subunit inactivated flu vaccine, Formulation 2010-2011",{"EARLY_PHASE1":3812,"PHASE1":3814,"PHASE2":3816,"PHASE3":3825,"PHASE4":3827,"NA":3829},{"trials":3813,"activeCount":8},[],{"trials":3815,"activeCount":8},[],{"trials":3817,"activeCount":8},[3818],{"nctId":3819,"briefTitle":3820,"status":61,"phases":3821,"primaryCompletion":370,"completion":107,"start":370,"enrollment":3822,"conditions":3823,"interventions":3824},"NCT01151059","Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects",[41],138,[23],[3810],{"trials":3826,"activeCount":8},[],{"trials":3828,"activeCount":8},[],{"trials":3830,"activeCount":8},[],{"intervention":3832,"totalTrials":127,"cells":3833},"Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009",{"EARLY_PHASE1":3834,"PHASE1":3836,"PHASE2":3838,"PHASE3":3847,"PHASE4":3849,"NA":3851},{"trials":3835,"activeCount":8},[],{"trials":3837,"activeCount":8},[],{"trials":3839,"activeCount":8},[3840],{"nctId":3841,"briefTitle":3842,"status":61,"phases":3843,"primaryCompletion":336,"completion":336,"start":168,"enrollment":3844,"conditions":3845,"interventions":3846},"NCT00748150","Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Subjects",[41],143,[17],[3832],{"trials":3848,"activeCount":8},[],{"trials":3850,"activeCount":8},[],{"trials":3852,"activeCount":8},[],{"intervention":3854,"totalTrials":127,"cells":3855},"serogroup B meningococcal vaccine",{"EARLY_PHASE1":3856,"PHASE1":3858,"PHASE2":3860,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3857,"activeCount":8},[],{"trials":3859,"activeCount":8},[],{"trials":3861,"activeCount":8},[3862],{"nctId":3863,"briefTitle":3864,"status":61,"phases":3865,"primaryCompletion":3866,"completion":3866,"start":3867,"enrollment":3868,"conditions":3869,"interventions":3870},"NCT00297817","Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents",[41],"2007-04","2006-02",203,[14],[3854,3854,3854],{"trials":3872,"activeCount":8},[],{"trials":3874,"activeCount":8},[],{"trials":3876,"activeCount":8},[],{"intervention":3878,"totalTrials":127,"cells":3879},"Fluad H5N1 Pandemic Influenza Vaccine",{"EARLY_PHASE1":3880,"PHASE1":3882,"PHASE2":3884,"PHASE3":3894,"PHASE4":3896,"NA":3898},{"trials":3881,"activeCount":8},[],{"trials":3883,"activeCount":8},[],{"trials":3885,"activeCount":8},[3886],{"nctId":3887,"briefTitle":3888,"status":61,"phases":3889,"primaryCompletion":1278,"completion":1278,"start":593,"enrollment":3890,"conditions":3891,"interventions":3893},"NCT00478816","Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines",[41],58,[3892],"Prophylaxis of Avian Influenza Vaccine",[3878],{"trials":3895,"activeCount":8},[],{"trials":3897,"activeCount":8},[],{"trials":3899,"activeCount":8},[],{"intervention":3901,"totalTrials":127,"cells":3902},"MenACWY-CRM Vaccine",{"EARLY_PHASE1":3903,"PHASE1":3905,"PHASE2":3907,"PHASE3":3918,"PHASE4":3920,"NA":3922},{"trials":3904,"activeCount":8},[],{"trials":3906,"activeCount":8},[],{"trials":3908,"activeCount":8},[3909],{"nctId":3910,"briefTitle":3911,"status":61,"phases":3912,"primaryCompletion":556,"completion":556,"start":3913,"enrollment":3914,"conditions":3915,"interventions":3916},"NCT00262028","Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children",[41],"2005-04",910,[531],[3901,3917],"MenACWY-PS Vaccine",{"trials":3919,"activeCount":8},[],{"trials":3921,"activeCount":8},[],{"trials":3923,"activeCount":8},[],{"intervention":3917,"totalTrials":127,"cells":3925},{"EARLY_PHASE1":3926,"PHASE1":3928,"PHASE2":3930,"PHASE3":3936,"PHASE4":3938,"NA":3940},{"trials":3927,"activeCount":8},[],{"trials":3929,"activeCount":8},[],{"trials":3931,"activeCount":8},[3932],{"nctId":3910,"briefTitle":3911,"status":61,"phases":3933,"primaryCompletion":556,"completion":556,"start":3913,"enrollment":3914,"conditions":3934,"interventions":3935},[41],[531],[3901,3917],{"trials":3937,"activeCount":8},[],{"trials":3939,"activeCount":8},[],{"trials":3941,"activeCount":8},[],{"intervention":3943,"totalTrials":127,"cells":3944},"aTIV",{"EARLY_PHASE1":3945,"PHASE1":3947,"PHASE2":3949,"PHASE3":3957,"PHASE4":3959,"NA":3961},{"trials":3946,"activeCount":8},[],{"trials":3948,"activeCount":8},[],{"trials":3950,"activeCount":8},[3951],{"nctId":3952,"briefTitle":3953,"status":61,"phases":3954,"primaryCompletion":379,"completion":379,"start":694,"enrollment":459,"conditions":3955,"interventions":3956},"NCT01879540","Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013\u002F2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age",[41],[26],[3943],{"trials":3958,"activeCount":8},[],{"trials":3960,"activeCount":8},[],{"trials":3962,"activeCount":8},[],{"intervention":521,"totalTrials":127,"cells":3964},{"EARLY_PHASE1":3965,"PHASE1":3967,"PHASE2":3969,"PHASE3":3975,"PHASE4":3977,"NA":3979},{"trials":3966,"activeCount":8},[],{"trials":3968,"activeCount":8},[],{"trials":3970,"activeCount":8},[3971],{"nctId":509,"briefTitle":510,"status":61,"phases":3972,"primaryCompletion":512,"completion":336,"start":305,"enrollment":513,"conditions":3973,"interventions":3974},[41],[515],[331,517,518,519,520,521,500],{"trials":3976,"activeCount":8},[],{"trials":3978,"activeCount":8},[],{"trials":3980,"activeCount":8},[],{"intervention":3982,"totalTrials":127,"cells":3983},"MF59C.1-adjuvanted subunit influenza vaccine",{"EARLY_PHASE1":3984,"PHASE1":3986,"PHASE2":3988,"PHASE3":3999,"PHASE4":4001,"NA":4003},{"trials":3985,"activeCount":8},[],{"trials":3987,"activeCount":8},[],{"trials":3989,"activeCount":8},[3990],{"nctId":3991,"briefTitle":3992,"status":61,"phases":3993,"primaryCompletion":3656,"completion":3656,"start":458,"enrollment":3994,"conditions":3995,"interventions":3997},"NCT01342796","Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects",[41],84,[23,17,3996,26],"Influenza Due to Unspecified Influenza Virus",[3982,3998],"Sub unit, Inactivated, Influenza vaccine",{"trials":4000,"activeCount":8},[],{"trials":4002,"activeCount":8},[],{"trials":4004,"activeCount":8},[],{"intervention":3998,"totalTrials":127,"cells":4006},{"EARLY_PHASE1":4007,"PHASE1":4009,"PHASE2":4011,"PHASE3":4017,"PHASE4":4019,"NA":4021},{"trials":4008,"activeCount":8},[],{"trials":4010,"activeCount":8},[],{"trials":4012,"activeCount":8},[4013],{"nctId":3991,"briefTitle":3992,"status":61,"phases":4014,"primaryCompletion":3656,"completion":3656,"start":458,"enrollment":3994,"conditions":4015,"interventions":4016},[41],[23,17,3996,26],[3982,3998],{"trials":4018,"activeCount":8},[],{"trials":4020,"activeCount":8},[],{"trials":4022,"activeCount":8},[],{"intervention":4024,"totalTrials":127,"cells":4025},"Group B Streptococcus Trivalent Vaccine - 20\u002F20\u002F20 μg",{"EARLY_PHASE1":4026,"PHASE1":4028,"PHASE2":4030,"PHASE3":4043,"PHASE4":4045,"NA":4047},{"trials":4027,"activeCount":8},[],{"trials":4029,"activeCount":8},[],{"trials":4031,"activeCount":8},[4032],{"nctId":4033,"briefTitle":4034,"status":61,"phases":4035,"primaryCompletion":2565,"completion":2810,"start":237,"enrollment":4036,"conditions":4037,"interventions":4039},"NCT01193920","Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age",[40,41],380,[4038],"Streptococcal Infections",[4024,4040,4041,4042],"Group B Streptococcus Trivalent Vaccine - 0.5\u002F0.5\u002F0.5 μg","Group B Streptococcus Trivalent Vaccine - 2.5\u002F2.5\u002F2.5 μg","Group B Streptococcus Trivalent Vaccine - 5\u002F5\u002F5 μg",{"trials":4044,"activeCount":8},[],{"trials":4046,"activeCount":8},[],{"trials":4048,"activeCount":8},[],{"intervention":4040,"totalTrials":127,"cells":4050},{"EARLY_PHASE1":4051,"PHASE1":4053,"PHASE2":4055,"PHASE3":4061,"PHASE4":4063,"NA":4065},{"trials":4052,"activeCount":8},[],{"trials":4054,"activeCount":8},[],{"trials":4056,"activeCount":8},[4057],{"nctId":4033,"briefTitle":4034,"status":61,"phases":4058,"primaryCompletion":2565,"completion":2810,"start":237,"enrollment":4036,"conditions":4059,"interventions":4060},[40,41],[4038],[4024,4040,4041,4042],{"trials":4062,"activeCount":8},[],{"trials":4064,"activeCount":8},[],{"trials":4066,"activeCount":8},[],{"intervention":4041,"totalTrials":127,"cells":4068},{"EARLY_PHASE1":4069,"PHASE1":4071,"PHASE2":4073,"PHASE3":4079,"PHASE4":4081,"NA":4083},{"trials":4070,"activeCount":8},[],{"trials":4072,"activeCount":8},[],{"trials":4074,"activeCount":8},[4075],{"nctId":4033,"briefTitle":4034,"status":61,"phases":4076,"primaryCompletion":2565,"completion":2810,"start":237,"enrollment":4036,"conditions":4077,"interventions":4078},[40,41],[4038],[4024,4040,4041,4042],{"trials":4080,"activeCount":8},[],{"trials":4082,"activeCount":8},[],{"trials":4084,"activeCount":8},[],{"intervention":4042,"totalTrials":127,"cells":4086},{"EARLY_PHASE1":4087,"PHASE1":4089,"PHASE2":4091,"PHASE3":4097,"PHASE4":4099,"NA":4101},{"trials":4088,"activeCount":8},[],{"trials":4090,"activeCount":8},[],{"trials":4092,"activeCount":8},[4093],{"nctId":4033,"briefTitle":4034,"status":61,"phases":4094,"primaryCompletion":2565,"completion":2810,"start":237,"enrollment":4036,"conditions":4095,"interventions":4096},[40,41],[4038],[4024,4040,4041,4042],{"trials":4098,"activeCount":8},[],{"trials":4100,"activeCount":8},[],{"trials":4102,"activeCount":8},[],{"intervention":4104,"totalTrials":127,"cells":4105},"Novartis Meningococcal (MenACWY-CRM) vaccine",{"EARLY_PHASE1":4106,"PHASE1":4108,"PHASE2":4110,"PHASE3":4119,"PHASE4":4121,"NA":4123},{"trials":4107,"activeCount":8},[],{"trials":4109,"activeCount":8},[],{"trials":4111,"activeCount":8},[4112],{"nctId":4113,"briefTitle":4114,"status":61,"phases":4115,"primaryCompletion":107,"completion":107,"start":921,"enrollment":4116,"conditions":4117,"interventions":4118},"NCT01018732","A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY",[41],155,[14,20],[4104],{"trials":4120,"activeCount":8},[],{"trials":4122,"activeCount":8},[],{"trials":4124,"activeCount":8},[],{"intervention":4126,"totalTrials":127,"cells":4127},"MenACWY-TT",{"EARLY_PHASE1":4128,"PHASE1":4130,"PHASE2":4132,"PHASE3":4141,"PHASE4":4143,"NA":4145},{"trials":4129,"activeCount":8},[],{"trials":4131,"activeCount":8},[],{"trials":4133,"activeCount":8},[4134],{"nctId":4135,"briefTitle":4136,"status":61,"phases":4137,"primaryCompletion":378,"completion":236,"start":985,"enrollment":4138,"conditions":4139,"interventions":4140},"NCT01994629","Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers",[41],202,[14],[549,4126],{"trials":4142,"activeCount":8},[],{"trials":4144,"activeCount":8},[],{"trials":4146,"activeCount":8},[],{"intervention":4148,"totalTrials":127,"cells":4149},"Adjuvanted Trivalent Influenza Virus Vaccine",{"EARLY_PHASE1":4150,"PHASE1":4152,"PHASE2":4154,"PHASE3":4162,"PHASE4":4164,"NA":4166},{"trials":4151,"activeCount":8},[],{"trials":4153,"activeCount":8},[],{"trials":4155,"activeCount":8},[4156],{"nctId":4157,"briefTitle":4158,"status":61,"phases":4159,"primaryCompletion":817,"completion":817,"start":143,"enrollment":459,"conditions":4160,"interventions":4161},"NCT01651104","Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects",[41],[26],[4148],{"trials":4163,"activeCount":8},[],{"trials":4165,"activeCount":8},[],{"trials":4167,"activeCount":8},[],{"intervention":340,"totalTrials":127,"cells":4169},{"EARLY_PHASE1":4170,"PHASE1":4172,"PHASE2":4174,"PHASE3":4180,"PHASE4":4182,"NA":4184},{"trials":4171,"activeCount":8},[],{"trials":4173,"activeCount":8},[],{"trials":4175,"activeCount":8},[4176],{"nctId":333,"briefTitle":334,"status":61,"phases":4177,"primaryCompletion":107,"completion":107,"start":336,"enrollment":337,"conditions":4178,"interventions":4179},[41],[29],[313,340,341],{"trials":4181,"activeCount":8},[],{"trials":4183,"activeCount":8},[],{"trials":4185,"activeCount":8},[],{"intervention":341,"totalTrials":127,"cells":4187},{"EARLY_PHASE1":4188,"PHASE1":4190,"PHASE2":4192,"PHASE3":4198,"PHASE4":4200,"NA":4202},{"trials":4189,"activeCount":8},[],{"trials":4191,"activeCount":8},[],{"trials":4193,"activeCount":8},[4194],{"nctId":333,"briefTitle":334,"status":61,"phases":4195,"primaryCompletion":107,"completion":107,"start":336,"enrollment":337,"conditions":4196,"interventions":4197},[41],[29],[313,340,341],{"trials":4199,"activeCount":8},[],{"trials":4201,"activeCount":8},[],{"trials":4203,"activeCount":8},[],{"intervention":4205,"totalTrials":127,"cells":4206},"Influenza Vaccine, Formulation 2008-2009",{"EARLY_PHASE1":4207,"PHASE1":4209,"PHASE2":4211,"PHASE3":4220,"PHASE4":4222,"NA":4224},{"trials":4208,"activeCount":8},[],{"trials":4210,"activeCount":8},[],{"trials":4212,"activeCount":8},[4213],{"nctId":4214,"briefTitle":4215,"status":61,"phases":4216,"primaryCompletion":168,"completion":168,"start":349,"enrollment":4217,"conditions":4218,"interventions":4219},"NCT00748813","Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008\u002F2009",[41],133,[23],[4205],{"trials":4221,"activeCount":8},[],{"trials":4223,"activeCount":8},[],{"trials":4225,"activeCount":8},[],{"intervention":533,"totalTrials":127,"cells":4227},{"EARLY_PHASE1":4228,"PHASE1":4230,"PHASE2":4232,"PHASE3":4238,"PHASE4":4240,"NA":4242},{"trials":4229,"activeCount":8},[],{"trials":4231,"activeCount":8},[],{"trials":4233,"activeCount":8},[4234],{"nctId":523,"briefTitle":524,"status":61,"phases":4235,"primaryCompletion":526,"completion":527,"start":528,"enrollment":529,"conditions":4236,"interventions":4237},[41],[531],[533,534,535,536,537,500,538,539],{"trials":4239,"activeCount":8},[],{"trials":4241,"activeCount":8},[],{"trials":4243,"activeCount":8},[],{"intervention":534,"totalTrials":127,"cells":4245},{"EARLY_PHASE1":4246,"PHASE1":4248,"PHASE2":4250,"PHASE3":4256,"PHASE4":4258,"NA":4260},{"trials":4247,"activeCount":8},[],{"trials":4249,"activeCount":8},[],{"trials":4251,"activeCount":8},[4252],{"nctId":523,"briefTitle":524,"status":61,"phases":4253,"primaryCompletion":526,"completion":527,"start":528,"enrollment":529,"conditions":4254,"interventions":4255},[41],[531],[533,534,535,536,537,500,538,539],{"trials":4257,"activeCount":8},[],{"trials":4259,"activeCount":8},[],{"trials":4261,"activeCount":8},[],{"intervention":535,"totalTrials":127,"cells":4263},{"EARLY_PHASE1":4264,"PHASE1":4266,"PHASE2":4268,"PHASE3":4274,"PHASE4":4276,"NA":4278},{"trials":4265,"activeCount":8},[],{"trials":4267,"activeCount":8},[],{"trials":4269,"activeCount":8},[4270],{"nctId":523,"briefTitle":524,"status":61,"phases":4271,"primaryCompletion":526,"completion":527,"start":528,"enrollment":529,"conditions":4272,"interventions":4273},[41],[531],[533,534,535,536,537,500,538,539],{"trials":4275,"activeCount":8},[],{"trials":4277,"activeCount":8},[],{"trials":4279,"activeCount":8},[],{"intervention":537,"totalTrials":127,"cells":4281},{"EARLY_PHASE1":4282,"PHASE1":4284,"PHASE2":4286,"PHASE3":4292,"PHASE4":4294,"NA":4296},{"trials":4283,"activeCount":8},[],{"trials":4285,"activeCount":8},[],{"trials":4287,"activeCount":8},[4288],{"nctId":523,"briefTitle":524,"status":61,"phases":4289,"primaryCompletion":526,"completion":527,"start":528,"enrollment":529,"conditions":4290,"interventions":4291},[41],[531],[533,534,535,536,537,500,538,539],{"trials":4293,"activeCount":8},[],{"trials":4295,"activeCount":8},[],{"trials":4297,"activeCount":8},[],{"intervention":538,"totalTrials":127,"cells":4299},{"EARLY_PHASE1":4300,"PHASE1":4302,"PHASE2":4304,"PHASE3":4310,"PHASE4":4312,"NA":4314},{"trials":4301,"activeCount":8},[],{"trials":4303,"activeCount":8},[],{"trials":4305,"activeCount":8},[4306],{"nctId":523,"briefTitle":524,"status":61,"phases":4307,"primaryCompletion":526,"completion":527,"start":528,"enrollment":529,"conditions":4308,"interventions":4309},[41],[531],[533,534,535,536,537,500,538,539],{"trials":4311,"activeCount":8},[],{"trials":4313,"activeCount":8},[],{"trials":4315,"activeCount":8},[],{"intervention":4317,"totalTrials":127,"cells":4318},"Influenza Trivalent Inactivated Vaccines",{"EARLY_PHASE1":4319,"PHASE1":4321,"PHASE2":4323,"PHASE3":4333,"PHASE4":4335,"NA":4337},{"trials":4320,"activeCount":8},[],{"trials":4322,"activeCount":8},[],{"trials":4324,"activeCount":8},[4325],{"nctId":4326,"briefTitle":4327,"status":61,"phases":4328,"primaryCompletion":620,"completion":349,"start":169,"enrollment":4329,"conditions":4330,"interventions":4332},"NCT00644540","Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study",[41],89,[4331],"FLU",[4317,4317],{"trials":4334,"activeCount":8},[],{"trials":4336,"activeCount":8},[],{"trials":4338,"activeCount":8},[],{"intervention":4340,"totalTrials":127,"cells":4341},"Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.",{"EARLY_PHASE1":4342,"PHASE1":4344,"PHASE2":4346,"PHASE3":4359,"PHASE4":4361,"NA":4363},{"trials":4343,"activeCount":8},[],{"trials":4345,"activeCount":8},[],{"trials":4347,"activeCount":8},[4348],{"nctId":4349,"briefTitle":4350,"status":61,"phases":4351,"primaryCompletion":304,"completion":1845,"start":144,"enrollment":4352,"conditions":4353,"interventions":4355},"NCT01272180","Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults",[41],484,[4354],"Invasive Meningococcal Disease",[4340,4356,4357,4358],"Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.","Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.","Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.",{"trials":4360,"activeCount":8},[],{"trials":4362,"activeCount":8},[],{"trials":4364,"activeCount":8},[],{"intervention":4356,"totalTrials":127,"cells":4366},{"EARLY_PHASE1":4367,"PHASE1":4369,"PHASE2":4371,"PHASE3":4377,"PHASE4":4379,"NA":4381},{"trials":4368,"activeCount":8},[],{"trials":4370,"activeCount":8},[],{"trials":4372,"activeCount":8},[4373],{"nctId":4349,"briefTitle":4350,"status":61,"phases":4374,"primaryCompletion":304,"completion":1845,"start":144,"enrollment":4352,"conditions":4375,"interventions":4376},[41],[4354],[4340,4356,4357,4358],{"trials":4378,"activeCount":8},[],{"trials":4380,"activeCount":8},[],{"trials":4382,"activeCount":8},[],{"intervention":4357,"totalTrials":127,"cells":4384},{"EARLY_PHASE1":4385,"PHASE1":4387,"PHASE2":4389,"PHASE3":4395,"PHASE4":4397,"NA":4399},{"trials":4386,"activeCount":8},[],{"trials":4388,"activeCount":8},[],{"trials":4390,"activeCount":8},[4391],{"nctId":4349,"briefTitle":4350,"status":61,"phases":4392,"primaryCompletion":304,"completion":1845,"start":144,"enrollment":4352,"conditions":4393,"interventions":4394},[41],[4354],[4340,4356,4357,4358],{"trials":4396,"activeCount":8},[],{"trials":4398,"activeCount":8},[],{"trials":4400,"activeCount":8},[],{"intervention":4358,"totalTrials":127,"cells":4402},{"EARLY_PHASE1":4403,"PHASE1":4405,"PHASE2":4407,"PHASE3":4413,"PHASE4":4415,"NA":4417},{"trials":4404,"activeCount":8},[],{"trials":4406,"activeCount":8},[],{"trials":4408,"activeCount":8},[4409],{"nctId":4349,"briefTitle":4350,"status":61,"phases":4410,"primaryCompletion":304,"completion":1845,"start":144,"enrollment":4352,"conditions":4411,"interventions":4412},[41],[4354],[4340,4356,4357,4358],{"trials":4414,"activeCount":8},[],{"trials":4416,"activeCount":8},[],{"trials":4418,"activeCount":8},[],{"intervention":1214,"totalTrials":127,"cells":4420},{"EARLY_PHASE1":4421,"PHASE1":4423,"PHASE2":4425,"PHASE3":4431,"PHASE4":4433,"NA":4435},{"trials":4422,"activeCount":8},[],{"trials":4424,"activeCount":8},[],{"trials":4426,"activeCount":8},[4427],{"nctId":1208,"briefTitle":1209,"status":61,"phases":4428,"primaryCompletion":107,"completion":325,"start":592,"enrollment":1211,"conditions":4429,"interventions":4430},[41],[14],[1199,1214],{"trials":4432,"activeCount":8},[],{"trials":4434,"activeCount":8},[],{"trials":4436,"activeCount":8},[],{"intervention":4438,"totalTrials":127,"cells":4439},"Influenza Virus Vaccine",{"EARLY_PHASE1":4440,"PHASE1":4442,"PHASE2":4444,"PHASE3":4454,"PHASE4":4456,"NA":4458},{"trials":4441,"activeCount":8},[],{"trials":4443,"activeCount":8},[],{"trials":4445,"activeCount":8},[4446],{"nctId":4447,"briefTitle":4448,"status":61,"phases":4449,"primaryCompletion":2285,"completion":1189,"start":64,"enrollment":4450,"conditions":4451,"interventions":4453},"NCT00264576","Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults",[41],613,[4452],"Influenza Disease; Flu",[4438],{"trials":4455,"activeCount":8},[],{"trials":4457,"activeCount":8},[],{"trials":4459,"activeCount":8},[],{"intervention":4461,"totalTrials":127,"cells":4462},"Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008",{"EARLY_PHASE1":4463,"PHASE1":4465,"PHASE2":4467,"PHASE3":4475,"PHASE4":4477,"NA":4479},{"trials":4464,"activeCount":8},[],{"trials":4466,"activeCount":8},[],{"trials":4468,"activeCount":8},[4469],{"nctId":4470,"briefTitle":4471,"status":61,"phases":4472,"primaryCompletion":512,"completion":512,"start":662,"enrollment":466,"conditions":4473,"interventions":4474},"NCT00518726","Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007\u002F2008) When Administered to NON Elderly AND Elderly Subjects",[41],[17],[4461],{"trials":4476,"activeCount":8},[],{"trials":4478,"activeCount":8},[],{"trials":4480,"activeCount":8},[],{"intervention":4482,"totalTrials":127,"cells":4483},"MenABCWY",{"EARLY_PHASE1":4484,"PHASE1":4486,"PHASE2":4488,"PHASE3":4499,"PHASE4":4501,"NA":4503},{"trials":4485,"activeCount":8},[],{"trials":4487,"activeCount":8},[],{"trials":4489,"activeCount":8},[4490],{"nctId":4491,"briefTitle":4492,"status":61,"phases":4493,"primaryCompletion":1690,"completion":4494,"start":3374,"enrollment":4495,"conditions":4496,"interventions":4497},"NCT02140762","Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents",[41],"2015-02",305,[14],[4482,4498],"MenACWY",{"trials":4500,"activeCount":8},[],{"trials":4502,"activeCount":8},[],{"trials":4504,"activeCount":8},[],{"intervention":4498,"totalTrials":127,"cells":4506},{"EARLY_PHASE1":4507,"PHASE1":4509,"PHASE2":4511,"PHASE3":4517,"PHASE4":4519,"NA":4521},{"trials":4508,"activeCount":8},[],{"trials":4510,"activeCount":8},[],{"trials":4512,"activeCount":8},[4513],{"nctId":4491,"briefTitle":4492,"status":61,"phases":4514,"primaryCompletion":1690,"completion":4494,"start":3374,"enrollment":4495,"conditions":4515,"interventions":4516},[41],[14],[4482,4498],{"trials":4518,"activeCount":8},[],{"trials":4520,"activeCount":8},[],{"trials":4522,"activeCount":8},[],{"intervention":4524,"totalTrials":127,"cells":4525},"MF59-eTIV-H5N1+ placebo \u002Fpandemic influenza vaccine",{"EARLY_PHASE1":4526,"PHASE1":4528,"PHASE2":4530,"PHASE3":4543,"PHASE4":4545,"NA":4547},{"trials":4527,"activeCount":8},[],{"trials":4529,"activeCount":8},[],{"trials":4531,"activeCount":8},[4532],{"nctId":4533,"briefTitle":4534,"status":61,"phases":4535,"primaryCompletion":620,"completion":949,"start":169,"enrollment":529,"conditions":4536,"interventions":4537},"NCT00620815","Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above",[41],[17],[4524,4538,4539,4540,4541,4542],"Pandemic influenza vaccine + placebo \u002FMF59-eTIV-H5N1","Pandemic influenza vaccine + seasonal influenza vaccine \u002Fpandemic influenza vaccine","Pandemic influenza vaccine + placebo \u002F MF59-eTIV-H5N1","Pandemic influenza vaccine + seasonal influenza vaccine \u002F pandemic influenza vaccine","MF59-eTIV-H5N1 + Placebo\u002Fpandemic influenza vaccine",{"trials":4544,"activeCount":8},[],{"trials":4546,"activeCount":8},[],{"trials":4548,"activeCount":8},[],{"intervention":4538,"totalTrials":127,"cells":4550},{"EARLY_PHASE1":4551,"PHASE1":4553,"PHASE2":4555,"PHASE3":4561,"PHASE4":4563,"NA":4565},{"trials":4552,"activeCount":8},[],{"trials":4554,"activeCount":8},[],{"trials":4556,"activeCount":8},[4557],{"nctId":4533,"briefTitle":4534,"status":61,"phases":4558,"primaryCompletion":620,"completion":949,"start":169,"enrollment":529,"conditions":4559,"interventions":4560},[41],[17],[4524,4538,4539,4540,4541,4542],{"trials":4562,"activeCount":8},[],{"trials":4564,"activeCount":8},[],{"trials":4566,"activeCount":8},[],{"intervention":4539,"totalTrials":127,"cells":4568},{"EARLY_PHASE1":4569,"PHASE1":4571,"PHASE2":4573,"PHASE3":4579,"PHASE4":4581,"NA":4583},{"trials":4570,"activeCount":8},[],{"trials":4572,"activeCount":8},[],{"trials":4574,"activeCount":8},[4575],{"nctId":4533,"briefTitle":4534,"status":61,"phases":4576,"primaryCompletion":620,"completion":949,"start":169,"enrollment":529,"conditions":4577,"interventions":4578},[41],[17],[4524,4538,4539,4540,4541,4542],{"trials":4580,"activeCount":8},[],{"trials":4582,"activeCount":8},[],{"trials":4584,"activeCount":8},[],{"intervention":4540,"totalTrials":127,"cells":4586},{"EARLY_PHASE1":4587,"PHASE1":4589,"PHASE2":4591,"PHASE3":4597,"PHASE4":4599,"NA":4601},{"trials":4588,"activeCount":8},[],{"trials":4590,"activeCount":8},[],{"trials":4592,"activeCount":8},[4593],{"nctId":4533,"briefTitle":4534,"status":61,"phases":4594,"primaryCompletion":620,"completion":949,"start":169,"enrollment":529,"conditions":4595,"interventions":4596},[41],[17],[4524,4538,4539,4540,4541,4542],{"trials":4598,"activeCount":8},[],{"trials":4600,"activeCount":8},[],{"trials":4602,"activeCount":8},[],{"intervention":4541,"totalTrials":127,"cells":4604},{"EARLY_PHASE1":4605,"PHASE1":4607,"PHASE2":4609,"PHASE3":4615,"PHASE4":4617,"NA":4619},{"trials":4606,"activeCount":8},[],{"trials":4608,"activeCount":8},[],{"trials":4610,"activeCount":8},[4611],{"nctId":4533,"briefTitle":4534,"status":61,"phases":4612,"primaryCompletion":620,"completion":949,"start":169,"enrollment":529,"conditions":4613,"interventions":4614},[41],[17],[4524,4538,4539,4540,4541,4542],{"trials":4616,"activeCount":8},[],{"trials":4618,"activeCount":8},[],{"trials":4620,"activeCount":8},[],{"intervention":4542,"totalTrials":127,"cells":4622},{"EARLY_PHASE1":4623,"PHASE1":4625,"PHASE2":4627,"PHASE3":4633,"PHASE4":4635,"NA":4637},{"trials":4624,"activeCount":8},[],{"trials":4626,"activeCount":8},[],{"trials":4628,"activeCount":8},[4629],{"nctId":4533,"briefTitle":4534,"status":61,"phases":4630,"primaryCompletion":620,"completion":949,"start":169,"enrollment":529,"conditions":4631,"interventions":4632},[41],[17],[4524,4538,4539,4540,4541,4542],{"trials":4634,"activeCount":8},[],{"trials":4636,"activeCount":8},[],{"trials":4638,"activeCount":8},[],{"intervention":4640,"totalTrials":127,"cells":4641},"Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine",{"EARLY_PHASE1":4642,"PHASE1":4644,"PHASE2":4646,"PHASE3":4657,"PHASE4":4659,"NA":4661},{"trials":4643,"activeCount":8},[],{"trials":4645,"activeCount":8},[],{"trials":4647,"activeCount":8},[4648],{"nctId":4649,"briefTitle":4650,"status":61,"phases":4651,"primaryCompletion":357,"completion":143,"start":213,"enrollment":4652,"conditions":4653,"interventions":4654},"NCT01367158","Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines",[41],440,[14,20],[4640,4655,4656],"Meningococcal (group B) multicomponent recombinant adsorbed vaccine","Tdap",{"trials":4658,"activeCount":8},[],{"trials":4660,"activeCount":8},[],{"trials":4662,"activeCount":8},[],{"intervention":4655,"totalTrials":127,"cells":4664},{"EARLY_PHASE1":4665,"PHASE1":4667,"PHASE2":4669,"PHASE3":4675,"PHASE4":4677,"NA":4679},{"trials":4666,"activeCount":8},[],{"trials":4668,"activeCount":8},[],{"trials":4670,"activeCount":8},[4671],{"nctId":4649,"briefTitle":4650,"status":61,"phases":4672,"primaryCompletion":357,"completion":143,"start":213,"enrollment":4652,"conditions":4673,"interventions":4674},[41],[14,20],[4640,4655,4656],{"trials":4676,"activeCount":8},[],{"trials":4678,"activeCount":8},[],{"trials":4680,"activeCount":8},[],{"intervention":4656,"totalTrials":127,"cells":4682},{"EARLY_PHASE1":4683,"PHASE1":4685,"PHASE2":4687,"PHASE3":4693,"PHASE4":4695,"NA":4697},{"trials":4684,"activeCount":8},[],{"trials":4686,"activeCount":8},[],{"trials":4688,"activeCount":8},[4689],{"nctId":4649,"briefTitle":4650,"status":61,"phases":4690,"primaryCompletion":357,"completion":143,"start":213,"enrollment":4652,"conditions":4691,"interventions":4692},[41],[14,20],[4640,4655,4656],{"trials":4694,"activeCount":8},[],{"trials":4696,"activeCount":8},[],{"trials":4698,"activeCount":8},[],{"intervention":4700,"totalTrials":127,"cells":4701},"Meningococcal (group B) multicomponent recombinant adsorbed vaccine.",{"EARLY_PHASE1":4702,"PHASE1":4704,"PHASE2":4706,"PHASE3":4716,"PHASE4":4718,"NA":4720},{"trials":4703,"activeCount":8},[],{"trials":4705,"activeCount":8},[],{"trials":4707,"activeCount":8},[4708],{"nctId":4709,"briefTitle":4710,"status":61,"phases":4711,"primaryCompletion":325,"completion":326,"start":921,"enrollment":4712,"conditions":4713,"interventions":4714},"NCT01027351","Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine",[41],163,[14],[4700,4715],"Meningococcal",{"trials":4717,"activeCount":8},[],{"trials":4719,"activeCount":8},[],{"trials":4721,"activeCount":8},[],{"intervention":4715,"totalTrials":127,"cells":4723},{"EARLY_PHASE1":4724,"PHASE1":4726,"PHASE2":4728,"PHASE3":4734,"PHASE4":4736,"NA":4738},{"trials":4725,"activeCount":8},[],{"trials":4727,"activeCount":8},[],{"trials":4729,"activeCount":8},[4730],{"nctId":4709,"briefTitle":4710,"status":61,"phases":4731,"primaryCompletion":325,"completion":326,"start":921,"enrollment":4712,"conditions":4732,"interventions":4733},[41],[14],[4700,4715],{"trials":4735,"activeCount":8},[],{"trials":4737,"activeCount":8},[],{"trials":4739,"activeCount":8},[],{"intervention":4741,"totalTrials":127,"cells":4742},"MF59 adjuvanted H5N1 influenza vaccine",{"EARLY_PHASE1":4743,"PHASE1":4745,"PHASE2":4747,"PHASE3":4756,"PHASE4":4758,"NA":4760},{"trials":4744,"activeCount":8},[],{"trials":4746,"activeCount":8},[],{"trials":4748,"activeCount":8},[4749],{"nctId":4750,"briefTitle":4751,"status":61,"phases":4752,"primaryCompletion":620,"completion":620,"start":556,"enrollment":4753,"conditions":4754,"interventions":4755},"NCT00382187","Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults",[41],40,[17],[4741],{"trials":4757,"activeCount":8},[],{"trials":4759,"activeCount":8},[],{"trials":4761,"activeCount":8},[],{"intervention":4763,"totalTrials":127,"cells":4764},"Surface antigen inactivated influenza vaccine",{"EARLY_PHASE1":4765,"PHASE1":4767,"PHASE2":4769,"PHASE3":4778,"PHASE4":4780,"NA":4782},{"trials":4766,"activeCount":8},[],{"trials":4768,"activeCount":8},[],{"trials":4770,"activeCount":8},[4771],{"nctId":4772,"briefTitle":4773,"status":61,"phases":4774,"primaryCompletion":591,"completion":591,"start":512,"enrollment":4775,"conditions":4776,"interventions":4777},"NCT00518453","Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008",[41],129,[17],[4763],{"trials":4779,"activeCount":8},[],{"trials":4781,"activeCount":8},[],{"trials":4783,"activeCount":8},[],{"intervention":4785,"totalTrials":127,"cells":4786},"H5N1 pandemic Influenza vaccine 3.75µg",{"EARLY_PHASE1":4787,"PHASE1":4789,"PHASE2":4791,"PHASE3":4801,"PHASE4":4803,"NA":4805},{"trials":4788,"activeCount":8},[],{"trials":4790,"activeCount":8},[],{"trials":4792,"activeCount":8},[4793],{"nctId":4794,"briefTitle":4795,"status":61,"phases":4796,"primaryCompletion":1158,"completion":1158,"start":429,"enrollment":4797,"conditions":4798,"interventions":4799},"NCT00914771","Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects",[41],722,[3368],[4785,4800],"H5N1 pandemic Influenza vaccine 7.5µg",{"trials":4802,"activeCount":8},[],{"trials":4804,"activeCount":8},[],{"trials":4806,"activeCount":8},[],{"intervention":4800,"totalTrials":127,"cells":4808},{"EARLY_PHASE1":4809,"PHASE1":4811,"PHASE2":4813,"PHASE3":4819,"PHASE4":4821,"NA":4823},{"trials":4810,"activeCount":8},[],{"trials":4812,"activeCount":8},[],{"trials":4814,"activeCount":8},[4815],{"nctId":4794,"briefTitle":4795,"status":61,"phases":4816,"primaryCompletion":1158,"completion":1158,"start":429,"enrollment":4797,"conditions":4817,"interventions":4818},[41],[3368],[4785,4800],{"trials":4820,"activeCount":8},[],{"trials":4822,"activeCount":8},[],{"trials":4824,"activeCount":8},[],{"intervention":4826,"totalTrials":127,"cells":4827},"Group B streptococcus vaccine",{"EARLY_PHASE1":4828,"PHASE1":4830,"PHASE2":4832,"PHASE3":4844,"PHASE4":4846,"NA":4848},{"trials":4829,"activeCount":8},[],{"trials":4831,"activeCount":8},[],{"trials":4833,"activeCount":8},[4834],{"nctId":4835,"briefTitle":4836,"status":61,"phases":4837,"primaryCompletion":4838,"completion":2810,"start":369,"enrollment":4839,"conditions":4840,"interventions":4843},"NCT01412801","Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings",[41],"2012-10",270,[4038,4841,4842],"Gram-Positive Bacterial Infections","Bacterial Infections",[4826],{"trials":4845,"activeCount":8},[],{"trials":4847,"activeCount":8},[],{"trials":4849,"activeCount":8},[],{"intervention":561,"totalTrials":127,"cells":4851},{"EARLY_PHASE1":4852,"PHASE1":4854,"PHASE2":4856,"PHASE3":4862,"PHASE4":4864,"NA":4866},{"trials":4853,"activeCount":8},[],{"trials":4855,"activeCount":8},[],{"trials":4857,"activeCount":8},[4858],{"nctId":553,"briefTitle":554,"status":61,"phases":4859,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":4860,"interventions":4861},[41],[20],[549,520,518,519,500,561],{"trials":4863,"activeCount":8},[],{"trials":4865,"activeCount":8},[],{"trials":4867,"activeCount":8},[],{"intervention":4869,"totalTrials":127,"cells":4870},"H7N9c low dose with adjuvant",{"EARLY_PHASE1":4871,"PHASE1":4873,"PHASE2":4886,"PHASE3":4888,"PHASE4":4890,"NA":4892},{"trials":4872,"activeCount":8},[],{"trials":4874,"activeCount":8},[4875],{"nctId":4876,"briefTitle":4877,"status":61,"phases":4878,"primaryCompletion":747,"completion":747,"start":379,"enrollment":4879,"conditions":4880,"interventions":4882},"NCT01928472","Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years",[40],402,[4881],"H7N9 Influenza",[4869,4883,4884,4885],"H7N9c medium dose with adjuvant","H7N9c high dose with adjuvant","H7N9c high dose without adjuvant",{"trials":4887,"activeCount":8},[],{"trials":4889,"activeCount":8},[],{"trials":4891,"activeCount":8},[],{"trials":4893,"activeCount":8},[],{"intervention":4883,"totalTrials":127,"cells":4895},{"EARLY_PHASE1":4896,"PHASE1":4898,"PHASE2":4904,"PHASE3":4906,"PHASE4":4908,"NA":4910},{"trials":4897,"activeCount":8},[],{"trials":4899,"activeCount":8},[4900],{"nctId":4876,"briefTitle":4877,"status":61,"phases":4901,"primaryCompletion":747,"completion":747,"start":379,"enrollment":4879,"conditions":4902,"interventions":4903},[40],[4881],[4869,4883,4884,4885],{"trials":4905,"activeCount":8},[],{"trials":4907,"activeCount":8},[],{"trials":4909,"activeCount":8},[],{"trials":4911,"activeCount":8},[],{"intervention":4884,"totalTrials":127,"cells":4913},{"EARLY_PHASE1":4914,"PHASE1":4916,"PHASE2":4922,"PHASE3":4924,"PHASE4":4926,"NA":4928},{"trials":4915,"activeCount":8},[],{"trials":4917,"activeCount":8},[4918],{"nctId":4876,"briefTitle":4877,"status":61,"phases":4919,"primaryCompletion":747,"completion":747,"start":379,"enrollment":4879,"conditions":4920,"interventions":4921},[40],[4881],[4869,4883,4884,4885],{"trials":4923,"activeCount":8},[],{"trials":4925,"activeCount":8},[],{"trials":4927,"activeCount":8},[],{"trials":4929,"activeCount":8},[],{"intervention":4885,"totalTrials":127,"cells":4931},{"EARLY_PHASE1":4932,"PHASE1":4934,"PHASE2":4940,"PHASE3":4942,"PHASE4":4944,"NA":4946},{"trials":4933,"activeCount":8},[],{"trials":4935,"activeCount":8},[4936],{"nctId":4876,"briefTitle":4877,"status":61,"phases":4937,"primaryCompletion":747,"completion":747,"start":379,"enrollment":4879,"conditions":4938,"interventions":4939},[40],[4881],[4869,4883,4884,4885],{"trials":4941,"activeCount":8},[],{"trials":4943,"activeCount":8},[],{"trials":4945,"activeCount":8},[],{"trials":4947,"activeCount":8},[],{"intervention":4949,"totalTrials":127,"cells":4950},"H.pylori vaccines",{"EARLY_PHASE1":4951,"PHASE1":4953,"PHASE2":4962,"PHASE3":4964,"PHASE4":4966,"NA":4968},{"trials":4952,"activeCount":8},[],{"trials":4954,"activeCount":8},[4955],{"nctId":4956,"briefTitle":4957,"status":61,"phases":4958,"primaryCompletion":280,"completion":279,"start":2427,"enrollment":459,"conditions":4959,"interventions":4961},"NCT00736476","Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults",[40],[4960],"Helicobacter Pylori Infection",[4949],{"trials":4963,"activeCount":8},[],{"trials":4965,"activeCount":8},[],{"trials":4967,"activeCount":8},[],{"trials":4969,"activeCount":8},[],{"intervention":4971,"totalTrials":127,"cells":4972},"Monovalent GBS-CRM glycoconjugate vaccine",{"EARLY_PHASE1":4973,"PHASE1":4975,"PHASE2":4985,"PHASE3":4987,"PHASE4":4989,"NA":4991},{"trials":4974,"activeCount":8},[],{"trials":4976,"activeCount":8},[4977],{"nctId":4978,"briefTitle":4979,"status":61,"phases":4980,"primaryCompletion":2660,"completion":544,"start":629,"enrollment":4981,"conditions":4982,"interventions":4984},"NCT00657683","A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age",[40],65,[4983],"Invasive Group B Streptococcus (GBS) Disease",[4971],{"trials":4986,"activeCount":8},[],{"trials":4988,"activeCount":8},[],{"trials":4990,"activeCount":8},[],{"trials":4992,"activeCount":8},[],{"intervention":4994,"totalTrials":127,"cells":4995},"Haemophilus influenzae type b",{"EARLY_PHASE1":4996,"PHASE1":4998,"PHASE2":5006,"PHASE3":5008,"PHASE4":5010,"NA":5012},{"trials":4997,"activeCount":8},[],{"trials":4999,"activeCount":8},[5000],{"nctId":5001,"briefTitle":5002,"status":61,"phases":5003,"primaryCompletion":2427,"completion":2427,"start":168,"enrollment":4753,"conditions":5004,"interventions":5005},"NCT00734565","Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b",[40],[1395],[4994],{"trials":5007,"activeCount":8},[],{"trials":5009,"activeCount":8},[],{"trials":5011,"activeCount":8},[],{"trials":5013,"activeCount":8},[],{"intervention":5015,"totalTrials":127,"cells":5016},"GBS glycoconjugate vaccine",{"EARLY_PHASE1":5017,"PHASE1":5019,"PHASE2":5027,"PHASE3":5029,"PHASE4":5031,"NA":5033},{"trials":5018,"activeCount":8},[],{"trials":5020,"activeCount":8},[5021],{"nctId":5022,"briefTitle":5023,"status":61,"phases":5024,"primaryCompletion":544,"completion":358,"start":592,"enrollment":3338,"conditions":5025,"interventions":5026},"NCT00645346","A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of Age",[40],[4983],[5015],{"trials":5028,"activeCount":8},[],{"trials":5030,"activeCount":8},[],{"trials":5032,"activeCount":8},[],{"trials":5034,"activeCount":8},[],{"intervention":5036,"totalTrials":127,"cells":5037},"Group B streptococcus (GBS) vaccine- low dose",{"EARLY_PHASE1":5038,"PHASE1":5040,"PHASE2":5052,"PHASE3":5054,"PHASE4":5056,"NA":5058},{"trials":5039,"activeCount":8},[],{"trials":5041,"activeCount":8},[5042],{"nctId":5043,"briefTitle":5044,"status":61,"phases":5045,"primaryCompletion":212,"completion":4838,"start":5046,"enrollment":5047,"conditions":5048,"interventions":5050},"NCT01150123","Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women",[40],"2010-05",678,[5049],"Group B Streptococcus",[5036,5051],"Group B streptococcus (GBS) vaccine- High dose",{"trials":5053,"activeCount":8},[],{"trials":5055,"activeCount":8},[],{"trials":5057,"activeCount":8},[],{"trials":5059,"activeCount":8},[],{"intervention":5051,"totalTrials":127,"cells":5061},{"EARLY_PHASE1":5062,"PHASE1":5064,"PHASE2":5070,"PHASE3":5072,"PHASE4":5074,"NA":5076},{"trials":5063,"activeCount":8},[],{"trials":5065,"activeCount":8},[5066],{"nctId":5043,"briefTitle":5044,"status":61,"phases":5067,"primaryCompletion":212,"completion":4838,"start":5046,"enrollment":5047,"conditions":5068,"interventions":5069},[40],[5049],[5036,5051],{"trials":5071,"activeCount":8},[],{"trials":5073,"activeCount":8},[],{"trials":5075,"activeCount":8},[],{"trials":5077,"activeCount":8},[],{"intervention":5079,"totalTrials":127,"cells":5080},"helicobacter pylori vaccine",{"EARLY_PHASE1":5081,"PHASE1":5083,"PHASE2":5100,"PHASE3":5102,"PHASE4":5104,"NA":5106},{"trials":5082,"activeCount":8},[],{"trials":5084,"activeCount":8},[5085],{"nctId":5086,"briefTitle":5087,"status":61,"phases":5088,"primaryCompletion":5089,"completion":5090,"start":5091,"enrollment":5092,"conditions":5093,"interventions":5099},"NCT00613665","Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults",[40],"2001-12","2002-04","2001-02",113,[5094,5095,5096,5097,5098],"Helicobacter Pylori","Gastritis","Gastric Cancer","Gastroduodenal Ulcers","Lymphoma",[5079,5079,5079,5079,5079,5079],{"trials":5101,"activeCount":8},[],{"trials":5103,"activeCount":8},[],{"trials":5105,"activeCount":8},[],{"trials":5107,"activeCount":8},[],{"intervention":5109,"totalTrials":127,"cells":5110},"Group B streptococcus (GBS) vaccine",{"EARLY_PHASE1":5111,"PHASE1":5113,"PHASE2":5123,"PHASE3":5125,"PHASE4":5127,"NA":5129},{"trials":5112,"activeCount":8},[],{"trials":5114,"activeCount":8},[5115],{"nctId":5116,"briefTitle":5117,"status":61,"phases":5118,"primaryCompletion":1533,"completion":348,"start":921,"enrollment":5119,"conditions":5120,"interventions":5122},"NCT01053767","A Study to Assess the Persistence of Two GBS Antibodies in Women Previously Immunized With a GBS Vaccine",[40],95,[5121],"Group B Streptococcus (GBS) Disease",[5109],{"trials":5124,"activeCount":8},[],{"trials":5126,"activeCount":8},[],{"trials":5128,"activeCount":8},[],{"trials":5130,"activeCount":8},[],{"intervention":5132,"totalTrials":127,"cells":5133},"Swine Influenza",{"EARLY_PHASE1":5134,"PHASE1":5136,"PHASE2":5146,"PHASE3":5148,"PHASE4":5150,"NA":5152},{"trials":5135,"activeCount":8},[],{"trials":5137,"activeCount":8},[5138],{"nctId":5139,"briefTitle":5140,"status":61,"phases":5141,"primaryCompletion":747,"completion":747,"start":119,"enrollment":5142,"conditions":5143,"interventions":5145},"NCT01855945","Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to \u003C9 Years, Adolescents 9 to \u003C18 Years, Adults 18 to \u003C65 Years and Elderly 65 Years and Older.",[40],627,[5144],"Prophylaxis of A\u002FH3N2v Influenza",[5132],{"trials":5147,"activeCount":8},[],{"trials":5149,"activeCount":8},[],{"trials":5151,"activeCount":8},[],{"trials":5153,"activeCount":8},[],{"intervention":5155,"totalTrials":127,"cells":5156},"Acellular pertussis vaccine",{"EARLY_PHASE1":5157,"PHASE1":5159,"PHASE2":5174,"PHASE3":5176,"PHASE4":5178,"NA":5180},{"trials":5158,"activeCount":8},[],{"trials":5160,"activeCount":8},[5161],{"nctId":5162,"briefTitle":5163,"status":61,"phases":5164,"primaryCompletion":143,"completion":694,"start":5165,"enrollment":5166,"conditions":5167,"interventions":5170},"NCT01529645","Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years",[40],"2012-03",420,[2431,5168,2432,5169,2907],"Whooping Cough","Lockjaw",[5155,5171,5172,5173],"Tetanus, reduced diphtheria, and acellular pertussis vaccine","Licensed TdaP booster vaccine","Diphtheria and tetanus vaccine",{"trials":5175,"activeCount":8},[],{"trials":5177,"activeCount":8},[],{"trials":5179,"activeCount":8},[],{"trials":5181,"activeCount":8},[],{"intervention":5171,"totalTrials":127,"cells":5183},{"EARLY_PHASE1":5184,"PHASE1":5186,"PHASE2":5192,"PHASE3":5194,"PHASE4":5196,"NA":5198},{"trials":5185,"activeCount":8},[],{"trials":5187,"activeCount":8},[5188],{"nctId":5162,"briefTitle":5163,"status":61,"phases":5189,"primaryCompletion":143,"completion":694,"start":5165,"enrollment":5166,"conditions":5190,"interventions":5191},[40],[2431,5168,2432,5169,2907],[5155,5171,5172,5173],{"trials":5193,"activeCount":8},[],{"trials":5195,"activeCount":8},[],{"trials":5197,"activeCount":8},[],{"trials":5199,"activeCount":8},[],{"intervention":5172,"totalTrials":127,"cells":5201},{"EARLY_PHASE1":5202,"PHASE1":5204,"PHASE2":5210,"PHASE3":5212,"PHASE4":5214,"NA":5216},{"trials":5203,"activeCount":8},[],{"trials":5205,"activeCount":8},[5206],{"nctId":5162,"briefTitle":5163,"status":61,"phases":5207,"primaryCompletion":143,"completion":694,"start":5165,"enrollment":5166,"conditions":5208,"interventions":5209},[40],[2431,5168,2432,5169,2907],[5155,5171,5172,5173],{"trials":5211,"activeCount":8},[],{"trials":5213,"activeCount":8},[],{"trials":5215,"activeCount":8},[],{"trials":5217,"activeCount":8},[],{"intervention":5173,"totalTrials":127,"cells":5219},{"EARLY_PHASE1":5220,"PHASE1":5222,"PHASE2":5228,"PHASE3":5230,"PHASE4":5232,"NA":5234},{"trials":5221,"activeCount":8},[],{"trials":5223,"activeCount":8},[5224],{"nctId":5162,"briefTitle":5163,"status":61,"phases":5225,"primaryCompletion":143,"completion":694,"start":5165,"enrollment":5166,"conditions":5226,"interventions":5227},[40],[2431,5168,2432,5169,2907],[5155,5171,5172,5173],{"trials":5229,"activeCount":8},[],{"trials":5231,"activeCount":8},[],{"trials":5233,"activeCount":8},[],{"trials":5235,"activeCount":8},[],{"intervention":549,"totalTrials":5237,"cells":5238},12,{"EARLY_PHASE1":5239,"PHASE1":5241,"PHASE2":5243,"PHASE3":5257,"PHASE4":5294,"NA":5296},{"trials":5240,"activeCount":8},[],{"trials":5242,"activeCount":8},[],{"trials":5244,"activeCount":8},[5245,5249,5253],{"nctId":4135,"briefTitle":4136,"status":61,"phases":5246,"primaryCompletion":378,"completion":236,"start":985,"enrollment":4138,"conditions":5247,"interventions":5248},[41],[14],[549,4126],{"nctId":541,"briefTitle":542,"status":61,"phases":5250,"primaryCompletion":544,"completion":545,"start":512,"enrollment":546,"conditions":5251,"interventions":5252},[41],[14],[549,518,550,500,551],{"nctId":553,"briefTitle":554,"status":61,"phases":5254,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":5255,"interventions":5256},[41],[20],[549,520,518,519,500,561],{"trials":5258,"activeCount":8},[5259,5267,5271,5275,5279,5283,5287],{"nctId":5260,"briefTitle":5261,"status":61,"phases":5262,"primaryCompletion":5263,"completion":5263,"start":1277,"enrollment":5264,"conditions":5265,"interventions":5266},"NCT01725217","Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia",[42],"2013-03",198,[14],[549],{"nctId":565,"briefTitle":566,"status":61,"phases":5268,"primaryCompletion":212,"completion":212,"start":402,"enrollment":568,"conditions":5269,"interventions":5270},[42],[14],[549,571,536,550,500],{"nctId":2126,"briefTitle":2127,"status":61,"phases":5272,"primaryCompletion":107,"completion":237,"start":592,"enrollment":2129,"conditions":5273,"interventions":5274},[42],[29],[2115,2132,549],{"nctId":2324,"briefTitle":2325,"status":61,"phases":5276,"primaryCompletion":2327,"completion":326,"start":237,"enrollment":2328,"conditions":5277,"interventions":5278},[42],[14,20],[549,549,2313],{"nctId":2657,"briefTitle":2658,"status":61,"phases":5280,"primaryCompletion":2660,"completion":401,"start":922,"enrollment":2661,"conditions":5281,"interventions":5282},[42],[29],[549,549,2646],{"nctId":2680,"briefTitle":2681,"status":61,"phases":5284,"primaryCompletion":357,"completion":357,"start":304,"enrollment":2683,"conditions":5285,"interventions":5286},[42],[14,20,2685,2686],[549,2669,2688,2689],{"nctId":5288,"briefTitle":5289,"status":61,"phases":5290,"primaryCompletion":369,"completion":369,"start":458,"enrollment":5291,"conditions":5292,"interventions":5293},"NCT01345721","Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine",[42],205,[14],[549],{"trials":5295,"activeCount":8},[],{"trials":5297,"activeCount":8},[5298,5305],{"nctId":5299,"briefTitle":5300,"status":61,"phases":5301,"primaryCompletion":4494,"completion":4494,"start":369,"enrollment":5302,"conditions":5303,"interventions":5304},"NCT01452464","Safety of MenACWY-CRM Vaccination in Adolescents",[],55397,[14],[549],{"nctId":5306,"briefTitle":5307,"status":61,"phases":5308,"primaryCompletion":5309,"completion":5309,"start":369,"enrollment":5310,"conditions":5311,"interventions":5312},"NCT01452438","Safety Surveillance of MenACWY-CRM Vaccine in Children",[],"2015-07",393,[14],[549],{"intervention":2434,"totalTrials":92,"cells":5314},{"EARLY_PHASE1":5315,"PHASE1":5317,"PHASE2":5319,"PHASE3":5321,"PHASE4":5327,"NA":5329},{"trials":5316,"activeCount":8},[],{"trials":5318,"activeCount":8},[],{"trials":5320,"activeCount":8},[],{"trials":5322,"activeCount":8},[5323],{"nctId":2424,"briefTitle":2425,"status":61,"phases":5324,"primaryCompletion":63,"completion":2427,"start":512,"enrollment":2428,"conditions":5325,"interventions":5326},[42],[20,2430,2431,2432],[2434,2413,2434],{"trials":5328,"activeCount":8},[],{"trials":5330,"activeCount":8},[5331],{"nctId":5332,"briefTitle":5333,"status":5334,"phases":5335,"primaryCompletion":5336,"completion":5336,"start":5263,"enrollment":8,"conditions":5337,"interventions":5338},"NCT01705379","Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older","WITHDRAWN",[],"2016-04",[14],[2434],{"intervention":5340,"totalTrials":127,"cells":5341},"Cell-derived A\u002FH1N1 influenza HA vaccine",{"EARLY_PHASE1":5342,"PHASE1":5344,"PHASE2":5346,"PHASE3":5348,"PHASE4":5350,"NA":5352},{"trials":5343,"activeCount":8},[],{"trials":5345,"activeCount":8},[],{"trials":5347,"activeCount":8},[],{"trials":5349,"activeCount":8},[],{"trials":5351,"activeCount":8},[],{"trials":5353,"activeCount":8},[5354],{"nctId":5355,"briefTitle":5356,"status":61,"phases":5357,"primaryCompletion":368,"completion":368,"start":327,"enrollment":5358,"conditions":5359,"interventions":5360},"NCT01098786","Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine",[],556,[283],[5340]]